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LIST OF ABBREVIATIONS 
 
 
ACS acute coronary syndrome 
ADP adenosine diphosphate 
AGE advanced glycation endproducts 
ASA acetyl salicylic acid 
ATP adenosine triphosphate 
AZT 3’-azido-3’-deoxythimidine (zidovudine) 
CAD coronary artery disease 
cAMP cyclic-3`5`-adenosine monophosphate 
CAPRIE Clopidogrel versus Aspirin in Patients at Risk for Ischaemic 
 Events 
CORE Collaborative Organization of RheothRx Evaluation 
COX cyclooxygenase enzyme 
DMEM Dulbecco’s modified Eagle’s medium 
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ESPS European Stroke Prevention Study 
ET-1 endothelin-1 
GP IIb/IIIa receptor platelet glycoprotein IIb/IIIa receptor 
Hct hematocrit 
ICAM intercellular adhesion molecule 
IL-1 interleukin-1 
iNOS inducible nitrogen monoxide synthase 
IS ischemic stroke 
LoRRca laser-assisted optical rotational cell analyzer 
LDL low density lipoprotein 
MCP-1 monocyte chemotactic protein-1 
MCSF macrophage colony stimulating factor 
NAD+ nicotinamide adenine dinucleotide 
NO nitrogen monoxide 
PAF platelet-activating factor 
PARP poly(ADP-ribose) polymerase 
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PBS phosphate buffered saline 
PCI percutan coronary intervention 
PFA-100 platelet function analyzer 
PGI2 prostacyclin 
PPP platelet-poor plasma 
PRP platelet-rich plasma 
RBC red blood cell 
ROS reactive oxygen species 
SEM standard error of mean 
TIA transient ischemic attack 
TNF tumor necrosis factor 
TXA2 thromboxan A2 
VCAM vascular cell adhesion molecule 
vWF von Willebrand factor 
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1. INTRODUCTION 
 
 
Atherothrombosis, defined as an atherosclerotic plaque disruption with 
superimposed thrombus formation represents the principal cause of morbidity and 
mortality in the industrialized countries with gaining importance in the developing 
nations as well. More than a century ago, Rudolph Virchow described first the principal 
factors involved in atherosclerosis and thrombus formation known as Virchow’s triad. It 
includes arterial wall damage with endothelial injury and dysfunction; the presence of 
various pro-thrombotic factors in the circulating blood and altered local 
hemorheological parameters. Despite the extended research on this field though, the 
exact pathomechanism is still debated and not fully elucidated yet. 
It is generally recognized, that atherosclerosis is a diffuse, ongoing, sterile 
inflammation initiated asymptomatically in early childhood as a “response to injury” 
[129]. The process begins with the functional impairment of the vascular endothelium 
lining the entire blood vessel system. This imperative autocrine/paracrine organ is 
composed of unique, multifunctional cells that provide an anticoagulant, but selectively 
permeable barrier essential in maintaining vascular homeostasis and vessel tone. 
Endothelial cells are also responsible for the regulated synthesis and secretion of potent 
vasodilator substances including prostacyclin (PGI2), bradykinin, adenosine and most 
importantly, nitric oxide (NO). NO has an inevitable physiological role in the regulation 
of blood pressure and local blood flow. Reduced synthesis of the molecule in 
atherosclerotic vessels contributes to an impaired vasomotor function, enhanced platelet 
aggregation and smooth muscle cell proliferation. On the contrary, vasoconstrictor 
agents such as endothelin-1 (ET-1), angiotensin II and thromboxane A2 (TXA2) offset 
the efficacy of the vasodilator molecules mentioned above contributing to the 
minute-by-minute control of the vascular tone and local blood flow. 
The endothelial regulation of inflammatory and immune responses is also of 
importance affecting the progression of atherosclerosis. While resting endothelial cells 
do not consecutively express molecules that can attract leukocytes from flowing blood, 
upon activation by thrombin, inflammatory cytokines (i.e., IL-1, TNF) or bacterial 
endotoxins these cells express a series of adhesion molecules on their luminal surface 
(i.e., VCAM, ICAM-1, E-selectin) initiating a multi-step process. Leukocytes first 
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transiently tether and roll on the endothelial surface, then adhere to it and migrate 
through the cell layer. Finally, they emigrate from the vascular lumen and move towards 
the site of tissue damage or infection. Following the early emigration of neutrophils, 
monocytes also leave the vascular bed promoted by the vascular cell adhesion molecules 
(VCAM). It is important to note that pro-oxidant molecules, present in hyperlipidemia, 
hyperglycemia and oxidative stress, upregulate the membrane expression of VCAM 
providing a plausible link to the early accumulation of monocytes within the vessel wall. 
Endothelial cells are considered to be the main source of the circulating von 
Willebrand factor. This highly multimeric glycoprotein has two distinct biological 
functions: it acts as the carrier of coagulation factor VIII and is also a cofactor required 
for platelets to bind to exposed subendothelial collagen upon vessel wall damage. 
Furthermore, plasma concentrations of von Willebrand factor might have potential as a 
marker for the assessment of endothelial dysfunction in vivo [12]. Elevated levels of the 
molecule have been demonstrated in patients with chronic cardio- and cerebrovascular 
diseases and were also associated with the prediction of adverse clinical events [66]; 
possibly by the promotion of thrombus formation. Further endothelium derived 
molecules, such as the pro-coagulant factor XIII and the anticoagulant thrombomodulin 
are pivotal in maintaining the critical balance of vascular homeostasis.  
 During the early phases of the atherosclerotic process, no gross morphologic 
changes can be detected within the vessel wall, except for the slight impairment of 
endothelium-dependent vasodilatation. Isolated macrophages containing negligible 
amounts of oxidized lipid droplets might appear. Subsequently, in response to the 
accumulating lipid particles, especially oxidized low density lipoprotein (LDL), 
endothelial and smooth muscle cells tend to secrete monocyte chemotactic protein-1 
(MCP-1) and macrophage colony stimulating factor (MCSF) that both promote 
monocyte chemotaxis, adhesion and their differentiation to macrophages. These cells 
further accumulate oxidized LDL leading to fatty streak formation. As lipid accretion 
overwhelms the uptake by macrophage-derived foam cells, small extracellular lipid 
pools appear within the vessel wall that - in conjunction with certain cytokines and 
platelet-derived growth factors - stimulate the proliferation and migration of adjacent 
smooth muscle cells forming the intimal coating of the expanding atherosclerotic 
plaque. Beneath this proteoglycan-rich layer, an organized lipid core develops and the 
lesion is classified as atheroma at this stage. Since fibrosis is not a predominant feature 
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of atheroma, it is structurally weak and might be susceptible of fissuring caused by 
mechanical forces. Otherwise, smooth muscle cells will form a fibrous cap consisting of 
collagen and connective tissue that might cause the substantial diminution of the 
vascular lumen. If the fibrous cap is destabilized by altered hemorheological parameters, 
increased mechanical forces or enzymatic degradation by metalloproteases (i.e., 
collagenase, gelatinase, elastase), the plaque may rupture exposing highly thrombogenic 
structures. Thus, platelets may contact and adhere to the subendothelial von Willebrand 
factor (vWf), collagen and fibronectin initiating their local activation [54]. This is 
followed by the synthesis and release of TXA2 and adenosine diphosphate (ADP) from 
α and dense granules, which proaggregatory molecules recruit additional thrombocytes 
to the site of vascular injury [51,54,71]. The common impact of these agonists is to 
activate specific signaling pathways and to generate a number of second messengers 
leading to the functional expression of glycoprotein (GP) IIb/IIIa receptors further 
promoting platelet aggregation. The resultant platelet-rich thrombi may induce partial or 
complete occlusion of the atherosclerotic vessel leading to the clinical manifestations of 
acute coronary syndrome (ACS), transient ischemic attack (TIA) or ischemic stroke (IS) 
[71,121]. 
The role of “classic” risk factors in the initiation and progression of 
atherosclerosis has been revealed a long time ago (i.e., age, male gender, hypertension, 
hyperlipidemia, genetic background, smoking, obesity and the lack of physical 
exercise). Further epidemiological studies have demonstrated that patients with diabetes 
mellitus or glucose intolerance are also at a higher risk for coronary heart disease [74]. 
Underlying mechanisms include the enhanced generation of cytokines, free radicals and 
advanced glycation endproducts (AGE). Glycosylation as well as the oxidative damage 
of proteins and lipoproteins lead to the structural and functional impairment of the 
affected molecules [38]. Impaired hemorheological parameters, particularly enhanced 
red blood cell aggregation are also of great importance [25]. Lipoprotein(a) is a 
well-described risk factor for coronary artery disease (CAD) that has a molecular 
structure similar to that of plasminogen. As a consequence, it may reduce plasmin 
formation and thus impair thrombolysis [87]. LDL, especially oxidized LDL diminishes 
endothelium-derived NO activity by the down-regulation of the endothelial nitrogen 
monoxide synthase (eNOS), decreased receptor-mediated NO release and NO 
inactivation via enhanced superoxide anion production [86]. Impaired homocysteine 
  7
metabolism has also been implicated as a risk factor for atherosclerosis [48]. While the 
exact pathomechanism is not completely elucidated yet, direct toxic effects on 
endothelial cells as well as more indirect mechanisms have been postulated. Enhanced 
cyclooxygenase (COX) activity has been documented in patients with essential 
hypertension reducing the availability of NO via free radical production. As a result, 
there is an increase regarding the biological activity of ET-1 and the expression of 
various adhesion molecules on the endothelial cell surface [148]. Several trials have 
consistently demonstrated the important role of oxygen free radicals in physiological 
processes, such as metabolism and cellular defense. On the contrary, they have been 
implicated in the development and progression of a wide range of diseases including 
atherosclerosis, ischemia-reperfusion injury, diabetes mellitus, inflammation and 
immunological disorders. When generated in excessive amounts, free radicals are 
considered to be highly toxic as they can oxidatively modify proteins, nucleic acids, 
carbohydrates and cause lipid peroxidation. Erythrocytes are one of the most susceptible 
cells as they are continuously exposed to high oxygen tensions. Under normal 
conditions, well-developed antioxidant defense mechanisms can render protection 
against the deleterious effects of constantly generated free radicals. In contrast, 
enhanced oxidative stress or spoiled protective mechanisms might lead to the functional 
impairment of the red blood cells (RBC). Structural damages are also initiated; 
alterations of the intracellular milieu and membrane characteristics might have a serious 
impact on hemorheological parameters (i.e., erythrocyte deformability and aggregation) 
leading to disturbed microcirculatory blood flow [8]. Employing drugs with the 
potential of scavenging these destructive radicals might be favorable throughout the 
treatment and prevention of cardiovascular diseases [58]. 
 To further emphasize the importance of hemorheological parameters and shear 
stress, we should note that early atherosclerotic lesions are site-specific, plaques do not 
occur randomly throughout the vascular system as would be expected by the systemic 
nature of risk factors [76]. Instead, they preferentially develop in areas where blood 
flow changes direction and where longitudinal forces exerted on the arteries are 
increased [50]. Also, in highly atherosclerotic vessels normal laminar flow conditions 
might not be maintained since the stenotic narrowings induce flow disturbances 
modifying cell-cell and cell-vessel interactions [5]. In these areas secondary streams 
might develop in directions away from the primary flow leading to the formation of a 
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apex of 
stenosis 
recirculation 
zones 
stagnation point 
vortex or a recirculation zone between the mainstream and the vascular wall 
(Figure 1.1.1). As a consequence, a prominent increase of shear stress occurs at the apex 
of the stenosis causing further endothelial damage, enhanced platelet activation and 
deposition. Analyses of the axial distribution of these depositions indicated that the 
greatest thrombocyte accumulation occurs at the apex of the atherosclerotic plaque 
leading to the progression of the vascular lesion. These findings highlight the inevitable 
preventive role of antiplatelet drugs diminishing shear-induced platelet aggregation and 
also the importance of blood viscosity contributing to the endothelial cell damage. 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.1: Effect of stenotic lesions on laminar blood flow. 
 
 Blood is a non-Newtonian suspension of erythrocytes, leukocytes, platelets, 
chylomicrons, carbohydrates, proteins and electrolytes. Its viscosity can be defined as an 
intrinsic resistance to flow caused by the internal friction developing between adjacent 
fluid layers [156]. At a given temperature, blood viscosity is primarily the function of 
the cell concentration, shear rate, red blood cell aggregation, deformability and plasma 
viscosity. As erythrocytes occupy the largest volume fraction of blood cells, hematocrit 
value (Hct) is considered to be one of the most dominant factors. Unlike for Newtonian 
fluids, blood viscosity is strongly dependent on the shear rate, it is significantly elevated 
under low-flow conditions when compared to that measured at higher shear rates. This 
shear-thinning behavior can be explained by the flow-dependent variations in 
erythrocyte aggregation and deformation [7]. Red blood cells tend to aggregate to form 
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rouleaux under low flow conditions when the shear stress is insufficient to disperse the 
cells. However, increasing flow rates lead to their progressive disaggregation and thus a 
noteworthy decrease in blood viscosity [9].  Normal human erythrocytes are remarkably 
deformable; they easily get elongated in response to higher shear rates with their long 
axis aligned with the flow. Red blood cell deformability is of crucial pathophysiological 
importance in the coronary microcirculation where the average capillary diameter might 
be as low as 3-5µm, well below the dimensions of an erythrocyte [157]. Plasma behaves 
as a Newtonian viscous fluid and also has a remarkable impact on regional blood flow. 
Plasma viscosity is a function of the concentration of suspended proteins, especially 
those with high molecular mass and structural asymmetry (i.e., fibrinogen, some 
globulins) and also lipid fractions. The importance of fibrinogen molecule is further 
emphasized by the fact that it is considered to be a significant determinant of red blood 
cell and platelet aggregation in vivo. 
 Several clinical and epidemiological studies have provided compelling evidence 
that hemorheological parameters are primary risk factors for the development and 
progression of cardio- and cerebrovascular diseases [78,6,37,18,139]. The coronary 
vessel system represents a special part of the circulation as there is a continuous 
fluctuation in blood flow, perfusion pressure and shear rate due to the cardiac cycle and 
the narrowest capillaries of the body can be found in the myocardium. Therefore the 
role of rheological alterations can be of superior importance than in any other parts of 
the circulatory system [78,6,157]. The Framingham Study initiated over half a century 
ago, the Puerto Rico Heart Health Program and the Honolulu Heart Program established 
the importance of hematocrit in the development and progression of cardiovascular 
diseases [73,140,18]. The Framingham and Northwick Park Studies demonstrated that 
elevated plasma fibrinogen concentration is a major cardiovascular risk factor [99]. The 
Monica Project revealed the great impact of whole blood and plasma viscosity for the 
first time. The Edinburgh Artery Study and the Caerphilly and Speedwell Collaborative 
Heart Disease Study provided further compelling evidence regarding the role of 
hemorheological variables in the development of cardiovascular diseases 
[144,174,84,89]. In the Physicians’ Health Study elevated baseline plasma fibrinogen 
concentration was associated with an increased risk of future myocardial infarction 
during a five-year follow-up period and was independent from any other risk factors 
[93]. Lowe et al. suggested blood viscosity to be associated with the extent of coronary 
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heart disease, but they could not demonstrate such a correlation regarding plasma 
viscosity [88]. Other authors revealed impaired hemorheological variables in patients 
with angiographically proven coronary artery disease, but they were unrelated to the 
clinical severity [123]. Previous data of our group also found hemorheological 
parameters (hematocrit, plasma fibrinogen, plasma and whole blood viscosity) to be 
significantly impaired in patients with ACS and chronic ischemic heart disease when 
compared to that of normal, healthy subjects [78,155]. Administering a nonionic block 
copolymer surfactant (RheothRx) to patients with acute myocardial infarction 
significantly reduced erythrocyte aggregation and also improved several 
hemorheological parameters highlighting its potential usefulness in a variety of diseases 
[154]. Kesmarky and his co-workers revealed major changes in some rheological and 
free radical associated parameters following percutaneous transluminal coronary 
angioplasty that might have a remarkable impact on the final outcome of the 
intervention [79]. Other trials confirmed the inevitable role of disturbed 
hemorheological variables in the development and progression of hypertensive 
retinopathy and other hypertension associated organ damages [101,158,161]. 
Habon et al. showed that the evaluation of various hemorheological parameters along 
with other diagnostic procedures could be of assistance in the clinical decision-making 
in patients with suspected ischemic heart disease [59]. 
 In addition to the aforementioned trials, numerous studies suggested the 
importance of altered rheological parameters in the development of cerebrovascular 
diseases as well [46]. The Edinburgh Artery Study revealed that hematocrit, whole 
blood and plasma viscosity and plasma fibrinogen concentration represent a major risk 
factor for stroke [91]. Furthermore, they have been implicated in the pathomechanism of 
lacunar brain infarcts and TIA [98]. Szapary at al. demonstrated that hematocrit, blood 
viscosity, plasma fibrinogen concentration, erythrocyte aggregation and deformability 
are significantly impaired in patients with chronic ischemic cerebrovascular disorders. 
In addition, the observed rheological alterations were in great agreement with the 
severity of the carotid artery stenosis [147]. 
 We should note that - in spite of the abundant, large case clinical trials cited 
above -, most hemorheological measurements are still lacking a strict standardization. 
Numerous devices exist aiming to characterize red blood cell aggregation; however, a 
widely accepted, “gold standard” method is not available to date. The Myrenne MA-1 
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was the first, easy to operate aggregometer and is still the most commonly utilized 
apparatus characterizing erythrocyte aggregation photometrically. Besides its great 
advantages (i.e., minimal amount of blood required for a test, short measurement time), 
the Myrenne has several limitations including the lack of temperature control and the 
limited amount of data provided by the basic instrument. A number of methods and 
devices have been developed to assess red blood cell deformability (St. Georges` 
filtrometer, ektacytometer, LoRRca), however, most of the tests are time consuming and 
the results are hardly comparable. Although numerous whole blood viscometers exist on 
the market providing accurate viscosity measurements, unfortunately, most of the tests 
are time consuming, have a potential biohazard risk and thus they are inappropriate for 
rapid, bedside testing. Thus, the development of a fast, reliable and accurate whole 
blood viscometer providing rapidly available, comparable and consistent data is 
emerging. The employment of standardized hemorheological methods might promote 
further epidemiological studies evaluating associations between blood rheology and 
various diseases. 
 As detailed previously, numerous risk factors have been identified to date 
damaging the cell layer providing the internal lining of the vascular system and thus 
promoting endothelial dysfunction and the expansion of atherosclerosis. Following its 
initiation in early childhood this sterile inflammation progresses over time and 
culminates in plaque formation. Upon the rupture of these lesions occlusive thrombi 
might develop leading to the clinical manifestations of ischemic vascular diseases. We 
should also note the great importance of blood rheology in atherosclerotic vessels as 
impaired hemorheological parameters might further reduce microcirculatory blood flow 
thus enhancing clinical symptoms caused by the pre-existing stenotic lesions.  
 Individually controlled and adjusted antiplatelet therapy has an exceptional 
importance in the therapy of ischemic vascular disorders and also throughout the 
primary and secondary prevention. Detecting abnormal hemorheological parameters, 
most importantly elevated whole blood viscosity profiles might assist physicians to 
modify them favorably in the near future and thus further reduce the morbidity and 
mortality of cardio- and cerebrovascular diseases. 
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2. AIMS OF THE INVESTIGATIONS 
 
 
1. To assess the efficacy of conventional antiplatelet medications (acetyl salicylic 
acid and thienopyridine derivates) via platelet aggregometry and to investigate the 
prevalence of non-responder subjects in a large patient population with chronic 
cardio- and cerebrovascular diseases. 
 
2. To monitor the platelet function of previously enrolled cooperative individuals 
with chronic vascular diseases up to two years. Meanwhile, we evaluate the 
hypothesis that the sensitivity to a fixed-dose antiplatelet medication progressively 
decreases during long-term therapy. 
 
3. To correlate the long-term prevalence of adverse clinical events (recurrent acute 
coronary syndrome, stroke or TIA) with the efficacy of the antiplatelet medication 
estimated by optical platelet aggregometry in a subset of our patients. 
 
4. To evaluate the hypothesis that poly(ADP-ribose) polymerase inhibitors with 
adenine-like molecular structure - acting as competitive antagonists - can 
effectively interfere with ADP-induced platelet aggregation. Furthermore, we 
intend to explore whether the experimental PARP inhibitors can antagonize 
heparin-induced platelet hyperreactivity. 
 
5. To test the reliability and reproducibility of a newly developed scanning capillary 
viscometer. To emphasize the importance of standardization, we intend to provide 
direct comparisons between the results obtained by the Rheolog™ and data 
collected using cone-plate and Couette viscometer systems over a wide range of 
shear rates. Our further aim is to assess the effects of storage time and storage 
temperature on whole blood viscosity profiles. 
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3. RESISTANCE TO ROUTINE ANTIPLATELET MEDICATION AND 
THE EFFICACY OF LONG-TERM ASPIRIN AND THIENOPYRIDINE 
THERAPIES 
 
 
3.1 Introduction 
  
 Cardio- and cerebrovascular diseases are the most frequent causes of morbidity 
and mortality in the developed nations with growing importance in the developing 
countries as well. Resting platelets are biconvex, discoid bodies that circulate as 
individual cells without adhering to the normal vascular endothelium [54]. Although at 
sites of vessel injury thrombocytes play a central role in the physiology of primary 
hemostasis, their possible role in atherogenesis has only been recently revealed 
[55,122]. Angiographic and angioscopic studies have further demonstrated that 
pathological platelet activation and aggregation are pivotal events promoting 
intravascular thrombus formation [4,47,151].  
  Considering platelets’ crucial role in the development and progression of 
occlusive vascular diseases, numerous drugs with improved effectiveness have been 
developed to influence discrete mechanisms of clot formation (Figure 3.1.1). The 
cyclooxygenase inhibitor acetyl salicylic acid (ASA) was introduced into medical 
practice in 1899 and was mainly used for its analgesic, anti-inflammatory and 
antipyretic effects for a long time. Its ability to inhibit platelet aggregation was first 
revealed decades later and soon became the standard antithrombotic agent used in the 
clinical practice. Biochemically, ASA acetylates the hydroxyl group of the serin-530 
amino acid of cyclooxygenase, irreversibly inactivating both isoforms of the enzyme 
[114]. However, it is important to note that the serum concentration required to inhibit 
COX-2 activity is considerably higher than needed to inhibit COX-1. Numerous trials 
have verified its beneficial effect in the treatment of cardiovascular diseases [3,127], and 
the regular administration of aspirin has been the mainstay of both primary and 
secondary preventions. Multi-center studies involving large patient populations have 
provided gripping evidence that aspirin therapy provides a 25% relative risk reduction 
of acute coronary syndrome, ischemic stroke and vascular death over the placebo group 
[3,53,150]. In subjects with unstable angina, aspirin reduced the incidence of 
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myocardial infarction and coronary death by 68% within the first 30 days of follow-up, 
and by 62% after twelve month when compared to the control group [127]. In a placebo 
controlled trial performed among individuals with previous myocardial infarction, it 
diminished the incidence of recurrent ischemic periods by 50% and also cardiovascular 
mortality by 23% within the initial five weeks following the acute event [67]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.1: Possible mechanisms of platelet activation and the inhibitory effect 
of various antiplatelet drugs (G: G protein, PLC: phospholipase C, IP3: inositol 
triphosphate, DAG: diacylglycerol, PKC: protein kinase C, AC: adenyl cyclase, 
PDE: phosphodiesterase, AMP: adenosine monophosphate, PLA2: phospholipase 
A2, AA: arachidonic acid, PGG2: prostaglandin G2, PGH2: prostaglandin H2, 
TXA2: thromboxane A2). 
 
 The greater attention directed to the understanding of platelet pathophysiology 
led to the development of novel drugs with improved antiplatelet efficacy [132]. The 
metabolites of thienopyridine derivates (activated by the cytochrome P450 CYP3A4 
enzyme) selectively and irreversibly block the binding of adenosine diphosphate to the 
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P2Y12 receptor on the platelet surface [19,137]. These agents effectively interfere with 
platelet activation, degranulation and also reduce the expression of the active form of 
GP IIb/IIIa receptor on the platelet surface thus preventing the binding of fibrinogen to 
this complex. On a molar basis clopidogrel has greater antiplatelet efficacy than 
ticlopidine and serious side effects are also rare [3]. Numerous trials have verified the 
preventive value of thienopyridine derivates throughout the secondary prevention of 
ischemic vascular diseases. For instance, in a population of 3069 patients with previous 
transient ischemic attack or amaurosis fugax ticlopidine provided an additional 21% 
relative-risk reduction over aspirin monotherapy [63]. Also, the CAPRIE study 
indicated that clopidogrel has superior efficacy than ASA in terms of prevention of 
ischemic stroke, myocardial infarction and vascular death [17]. In patients with unstable 
angina or myocardial infarction without ST segment elevation the combination therapy 
of ASA and clopidogrel proved to have superior efficacy than aspirin alone [100]. 
 Dipyridamole is a well-known antiplatelet agent that has been available for 
many years. The drug reduces the uptake of adenosine into endothelial cells and 
erythrocytes in a dose dependent manner, so its local concentration available for platelet 
cyclic-3`5`-adenosine monophosphate (cAMP) synthesis increases. Also, dipyridamole 
inhibits phosphodiesterase enzyme activity thus raising the intracellular levels of cAMP 
and cGMP considerably [94]. Via these mechanisms, platelet aggregation is reduced 
significantly in response to various agonists, such as platelet-activating factor (PAF), 
collagen and ADP. Two large case clinical trials, the European Stroke Prevention 
Studies (ESPS) have examined in detail the benefits of aspirin and/or dipyridamole for 
the secondary prevention of ischemic stroke and TIA. Over the 2-year period of 
ESPS-1, it revealed that the combination therapy of ASA and dipyridamole decreased 
the relative risk of stroke by 16% over aspirin monotherapy [43]. The ESPS-2 trial 
demonstrated that dipyridamole monotherapy applied as part of the secondary 
prevention reduced the risk of recurrent ischemic stroke considerably; however, it did 
not diminish the rate of mortality [35].  
The final common pathway for platelet aggregation is the binding of fibrinogen 
to the GP IIb/IIIa complex [104,153]; blocking this receptor with a highly effective 
antagonist (e.g., eptifibatide) completely inhibits platelet aggregation induced by any of 
the agonists or even their combination [105,116].  
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Heparin is an anticoagulant agent used in the prevention and management of 
venous and arterial thrombosis as well as during invasive procedures. Although 
unfractionated heparin inhibits thrombin-induced platelet aggregation [40], the molecule 
conversely potentiates platelet TXA2 formation and thus enhances their aggregation 
provoked by a range of agonists, including ADP, PAF and epinephrine [2,133,172]. 
Most importantly, this effect is detectable in therapeutic serum concentrations applied to 
prevent clot formation [172]. Molecules binding to the ADP receptors on the platelet 
surface might have potential therapeutic benefits in counteracting this pro-thrombotic 
effect of unfractionated heparin. 
Despite the obvious beneficial effects of ASA, it fails to prevent the recurrence 
of serious atherothrombotic events throughout the secondary prevention in some 
patients and persistent platelet aggregation has also been suggested in a significant 
number of high-risk subjects (5 to 40%) [77,15,56]. These phenomena are often referred 
as “aspirin resistance”; however, the term remains poorly defined to date. It can imply 
the clinical inability of aspirin to protect individuals from ischemic vascular events 
despite the regular administration of the drug (clinical description) [11,170,20]. The 
laboratory definition describes the inability of aspirin to produce an anticipated effect on 
one or more laboratory tests of platelet function, such as inhibiting aggregation, 
thromboxane biosynthesis and causing the prolongation of bleeding time (biochemical 
aspirin resistance) [57,112,41,62]. The underlying mechanism of the drug resistance has 
not been completely elucidated yet, but may involve the activation of platelets by 
COX-independent pathways, ASA-insensitive biosynthesis of TXA2 caused by COX-1 
gene polymorphism, collagen-induced platelet hyperaggregability and some classic risk 
factors, such as smoking [16,41,52]. Also, homozygote individuals to the PlA2 allele 
might show reduced response to ASA therapy (Papp E. et al., unpublished data). While 
the existence of aspirin non-responder patients has been accepted for years, 
thienopyridine resistance has only been recently revealed [168]. It is also important to 
note that some recent trials indicated that patients might become progressively less 
sensitive to the applied antiplatelet medication over long-term follow-up [120,64].  
As mentioned previously, the occurrence of serious ischemic vascular events 
might be significantly reduced by the regular administration of aspirin or thienopyridine 
derivates. However, the laboratory monitoring of platelet function is not conducted 
routinely these days leading to the strategy of “one size fits all” for dosing ASA, 
  17
ticlopidine and clopidogrel as well [70]. Also, the pharmaceutical inactivation of distinct 
thrombocyte functions might increase the risk of serious bleeding complications. 
Considering the individual differences regarding the sensitivity to platelet-active agents, 
monitoring platelet function to predict the risk of treatment failures and to apply the 
lowest, but still efficient daily drug doses might be favorable throughout the secondary 
prevention of vascular disorders. Numerous laboratory techniques have been developed 
with the aim to assess the efficacy of routine antiplatelet therapy. Although the optimal 
test is still debated, the most widespread method is the optical aggregometry described 
by Born [13]. Measurements are performed in platelet-rich plasma in the presence of 
various agonists (ADP, collagen, epinephrine and arachidonic acid are employed most 
frequently); the rate and extent of increase in light transmission is recorded by a 
photometer for 10 or 20 minutes. Impedance aggregometry is an alternative assay 
performed in diluted, anticoagulated whole blood [126]. Upon the addition of a 
pro-aggregatory molecule (inductor) to the sample, platelet aggregates form around the 
surface of the electrodes. As a consequence, electric impedance increases that is 
monitored throughout the measurement. A recently developed platelet aggregometer is 
the platelet function analyzer (PFA-100), where the closure time of a 150μM diameter 
aperture of a coated nitrocellulose membrane is recorded by a computer program [85]. 
Collagen-ADP and collagen-epinephrine are applied generally to the surface of these 
filters. Additional methods include ACT (ability of platelets to decrease clotting time) 
and the determination of the serum extruded from a clot upon retraction [107]. 
Eikelboom and colleagues raised the possibility that measuring the urinary levels of 11-
dehydro thromboxane B2 can prospectively identify patients relatively resistant to the 
conventional aspirin therapy [41]. These subjects might benefit from higher daily ASA 
doses or the administration of thienopyridine derivates. Further studies are required to 
validate and standardize the results of laboratory tests mentioned above and to correlate 
them independently with the clinical outcome.  
 To investigate the effectiveness of routine antiplatelet drugs and to assess the 
prevalence of non-responder subjects, optical platelet aggregometry was performed in a 
large patient population. As an initial measurement we evaluated the efficacy of 
conventional antiplatelet medication in five distinct patient populations. Subsequently, 
the platelet function of cooperative participants was monitored regularly up to 
24 months (±1 month). Their antiplatelet medication was repeatedly adjusted or 
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modified according to the laboratory results. As little prospective data are available for 
follow-up in the literature to date, in a pilot study we correlated the long-term 
prevalence of adverse clinical events (recurrent acute coronary syndrome, stroke or 
TIA) with the efficacy of the antiplatelet medication in a subset of our patients.  
 
 
3.2 Patients and methods 
 
3.2.1 Initial visit 
 The efficacy of routine antiplatelet medication was initially evaluated in 2819 
patients (1664 males, 1155 females, mean age: 62±12 years) on aspirin, thienopyridine 
or combination therapy. Five subgroups were formed based on the indication of the 
antiplatelet drugs and the reliability of follow-up:  
• Subgroup I (patients with previous acute coronary syndromes followed-up at 
the First Department of Medicine, Division of Cardiology, University of Pecs, 
Medical School) 
149 subjects with previous acute coronary syndrome (91 males, 58 females, 
mean age: 65±12 years) were enrolled in this subgroup. These high-risk patients 
were strictly followed-up by a specialist in cardiology and were regularly 
controlled in our laboratory as well. The effectiveness of the antiplatelet 
medication was evaluated six months following the acute event. 
• Subgroup II (chronic cardiovascular inpatients at the Department of Cardiac 
Rehabilitation, State Hospital of Balatonfured) 
We elaborated the aggregometry results of 461 subjects with previous ACS 
(322 males, 139 females, mean age: 62±10 years) being under continuous 
medical attendance at the Department of Cardiac Rehabilitation, State Hospital, 
Balatonfured. During the entire cardiac rehabilitation program specialists in 
cardiology regularly and strictly controlled both the drug therapy and the 
compliance of these patients. Platelet aggregometry was performed at least six 
weeks following the acute event and on the second week of the rehabilitation 
program. 
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• Subgroup III (patients with chronic cardiovascular disease visiting the 
Outpatient Department of Cardiology, First Department of Medicine, 
University of Pecs, Medical School) 
The effectiveness of routine antiplatelet therapy was evaluated in 645 individuals 
with chronic cardiovascular disease (410 males, 235 females, mean age: 61±12 
years). Ischemic heart disease was the most common indications for the applied 
medication. Merely some of these patients were regularly seen by a cardiologist 
or followed-up by a physician between the acute event and the performed 
laboratory test. 
• Subgroup IV (patients with chronic cerebrovascular disease seen at the 
Department of Neurology, University of Pecs, Medical School) 
1206 subjects (662 males, 544 females, mean age: 60±11 years) with chronic 
cerebrovascular disease (at least 3 months following an acute event) were 
enrolled in this group. 881 and 325 patients experienced ischemic stroke and 
TIA, respectively. The individual diagnosis was confirmed using CT or MRI in 
each case. Neurologists did not control regularly the efficacy of the antiplatelet 
therapy and compliance of these subjects prior to the laboratory test. Besides the 
regular aspirin or thienopyridine medications 88% of these patients were on a 
neuroprotective agent (pentoxiphyllin, piracetam or vinpocetin). 
• Subgroup V (patients from various family practices in Baranya County) 
The efficacy of antiplatelet medication was estimated in 358 patients (181 males, 
177 females, mean age: 66±10 years) seen from six family practices in Baranya 
County. The most common indications for the antiplatelet therapy included 
ischemic heart disease, chronic phase cerebrovascular disease, or peripheral 
arterial disease in this subgroup. Merely some of these patients were regularly 
seen by a specialist or even by the general practitioner subsequent to the 
initiation of the platelet inhibitory therapy. 
 
 The efficacy of the antiplatelet therapy was evaluated in the entire patient 
population and in each subgroup separately. As we can note, the most widespread 
indication for the treatment was either ischemic heart disease or chronic cerebrovascular 
disease and a specialist in cardiology, neurology, or a family practitioner initiated the 
laboratory test in each case. Subjects with previous acute coronary syndrome or stroke 
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were enrolled at least 3 months subsequent to the acute event. According to our initial 
findings the antiplatelet efficacy of 300 and 325mg ASA/day was not different 
significantly, both of them are referred as a daily dose of 325mg in the further data 
analysis. Informed consent along with a detailed questionnaire assessing compliance 
were obtained from each patient at the laboratory visits. The institutional committee on 
human research approved the study. 
 
3.2.2 Patient follow-up 
Following the initial laboratory test we encouraged our patients from subgroups 
III, IV and V to join our follow-up study. 71% of the addressed subjects responded and 
were enrolled; the efficacy of their antiplatelet medication was monitored every 6 month 
(±1 month) for an average of 2 years (±1 month). If the applied low-dose (100 or 
200mg) ASA medication was proved to be ineffective on any of the visits, the daily 
dose of the drug was increased up to 325mg and an extra laboratory test was performed 
within four weeks to verify the efficacy of the modified treatment. If a patient on a 
higher daily aspirin dose (300 or 325mg) was found to be non-responder, the 
administration of a thienopyridine derivate (either 500mg ticlopidine or 75mg 
clopidogrel) was proposed and the test was repeated in a month. Further visits were 
completed according to the initial schedule. 
As part of the follow-up study, we also evaluated the hypothesis that the 
sensitivity to a fixed-dose antiplatelet medication progressively decreases during 
long-term therapy. The individual responsiveness to low and high daily doses of aspirin 
along with the platelet inhibitory effect of thienopyridine derivates were continuously 
monitored throughout the follow-up period. 
 
3.2.3 Prospective study 
In a prospective, pilot study the possible association between the ex vivo 
efficacy of the antiplatelet medication and the frequency of cardio- and cerebrovascular 
morbidity and mortality was evaluated. Results from 330 patients (186 males, 
144 females, mean age: 62±12 years) with baseline and repeated platelet aggregometry 
have been analyzed to date; the average follow-up period was 24 months (±2 months). 
Two subgroups were formed based on the prevalence of adverse clinical events within 
the study period: 1) 35 patients presenting an acute coronary syndrome or a 
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cerebrovascular event; 2) 295 subjects without any acute ischemic events. The efficacy 
of the applied antiplatelet medication was evaluated in the subgroups separately. 
 
3.2.4 Platelet aggregation measurements 
Fasting blood samples were collected into Vacutainer® tubes via antecubital 
venipuncture and were immediately mixed with 1:10 volume of trisodium citrate 
(3.8%). Platelet-rich plasma (PRP) was prepared by spinning the tubes at 150g for 10 
minutes. After carefully removing PRP, the remaining specimen was further centrifuged 
at 2500g for 10 minutes to obtain platelet-poor plasma (PPP). Aliquots of 450μl PRP or 
PPP were pipetted into glass cuvettes and 50μl of ADP (final concentrations: 5 and 
10μM), collagen (2μg/ml), or epinephrine (10μM) was added to the PRP so as to induce 
platelet aggregation. Epinephrine and collagen are widely accepted to estimate the 
antiplatelet efficacy of acetyl salicylic acid, while ADP is used to verify the 
effectiveness of thienopyridine derivates (Figure 3.2.1). Samples were incubated at 
37°C and continuously stirred at 1000rpm throughout the measurements. The 
aggregation curve was recorded for 10 minutes using a Carat TX-4 platelet 
aggregometer (Carat Ltd., Budapest, Hungary) utilizing the turbidimetric method 
described by Born [13] (Figure 3.2.2). Maximal platelet aggregation was expressed as a 
percentage of 100% light transmission, calibrated for each specimen. All measurements 
were completed within 2 hours following venipuncture. 
 
 
 
 
 
 
 
Figure 3.2.1: Characteristic platelet aggregation curves representing a control 
measurement, an effective ASA and an appropriate thienopyridine therapy. 
 
Initially we re-validated the normal range (mean±2SD) of maximal platelet 
aggregation for each agonist (Table 3.2.1) by performing the aggregometry test for 250 
drug-free, control subjects (140 males, 110 females, mean age: 35±12 years). The 
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antiplatelet therapy of a patient on aspirin was considered to be ineffective if the 
maximal aggregation indices achieved by collagen and epinephrine were not 
significantly different from that of controls [29]. In case of thienopyridine derivates the 
applied medication was considered to be inappropriate if the ADP (5μM) induced 
platelet aggregation was within the range established for untreated, healthy subjects 
[29]. Results acquired with 5 and 10μM ADP were in great agreement in all cases; the 
higher inductor concentration was employed to verify the data obtained with 5μM ADP. 
 
 
 
 
 
 
 
 
Figure 3.2.2: Carat TX-4 platelet aggregometer utilizing the light transmission method 
described by Born. 
 
Table 3.2.1: Reference ranges (average±2SD) for maximum platelet aggregation indices 
achieved by different agonists in the control population (ineffective antiplatelet 
therapy). ADP is accepted to assess the antiplatelet efficacy of thienopyridine derivates, 
while collagen and epinephrine are used to estimate the sensitivity to aspirin. 
Reference ranges for maximum platelet aggregation (average±2SD) 
ADP 5μM ADP 10μM Collagen 2μg/ml Epinephrine 10μM 
62-91% 62-91% 64-92% 60-88% 
 
All aggregation curves were automatically analyzed by the computer program of 
the platelet aggregometer and by two independent medical doctors who were blinded to 
the drug therapy of the subjects. 
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3.3 Results 
 
3.3.1 Initial visit 
94% of the recruited patients were on either aspirin or thienopyridine 
monotherapy; a drug combination (daily dose of 100 or 325mg ASA in combination 
with either 500mg ticlopidine or 75mg clopidogrel) was administered in merely 6% of 
the population (Table 3.3.1). We can note that most patients were on a low-dose ASA 
therapy, only 12% of the subjects took 325mg on a regular basis. Clopidogrel was 
administered slightly more frequently than the other thienopyridine derivate 
(Table 3.3.1).  
 
Table 3.3.1: Detailed antiplatelet medication of the study population recorded at the 
initial visit. 
Subgroups Antiplatelet drugs (mg) 
 ASA 100 ASA 200 ASA 325 TIC 500 CLP 75 COMB 
Subgroup I (%) 37 8 25 2 7 21 
Subgroup II (%) 65 10 3 7 6 9 
Subgroup III (%) 51 2 18 4 15 10 
Subgroup IV (%) 55 6 9 12 16 2 
Subgroup V (%) 58 10 17 4 9 2 
Total (%) 55 6 12 8 13 6 
 
Considering the total examined population of 2819 subjects, the applied 
antiplatelet medication was found to be ineffective in 31% according to our laboratory 
tests (Figure 3.3.1). Inadequate ASA monotherapy was recorded in 35% of our patients; 
however, we can note an obvious inverse correlation between the aspirin dosage and the 
ratio of non-responsive individuals: 40% vs. 21% observed at low and high daily ASA 
doses, respectively (Figure 3.3.1). The frequency of ineffective medication was found to 
be 21% among subjects on a thienopyridine derivate with no significant differences 
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between the antiplatelet efficacy of ticlopidine and clopidogrel. As anticipated, 
combination therapy was found to be effective in most cases (Figure 3.3.1). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.1: The ratio of non-responder patients considering all antiplatelet agents (all 
drugs). The prevalence of drug-insensitive platelet aggregation is also detailed in case of 
three different doses of acetyl salicylic acid (ASA), ticlopidine (TIC), clopidogrel (CLP) 
and combination therapy (Comb). Values recorded at the initial visit are shown. 
 
 45% of patients in subgroup I were on a low-dose aspirin monotherapy, 
ticlopidine and clopidogrel administration was recorded in 2% and 7%, respectively. A 
drug combination was employed in 21% representing the highest value among the 
subgroups. 30% of the population on 100mg ASA showed reduced sensitivity to the 
medication. When applying higher daily doses of the drug, the ratio of ineffective 
therapy progressively diminished and reached as low as 24% in case of 325mg aspirin a 
day. Thienopyridine derivates and combination therapy were found to be inappropriate 
in merely 18% and 9% of this subgroup, respectively (Table 3.3.2). 
 78% of subjects in subgroup II received ASA on a regular basis at the 
Department of Cardiac Rehabilitation. 12% of these individuals were found to be 
insensitive to the therapy despite the tight control provided by physicians and the 
medical staff. This value represents the lowest ratio of aspirin non-responders observed 
in any of the subgroups. While the proportion of adequate ticlopidine and clopidogrel 
therapies reached as high as 90% and 93%, respectively, the combination of aspirin and 
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a thienopyridine derivate proved to be appropriate in all patients in this subgroup 
(Table 3.3.2). 
According to the aggregometry tests, 38% of the 465 patients on a low-dose 
ASA in subgroup III were insensitive to the medication (Table 3.3.2). As anticipated, 
when increasing the daily dose of the drug to 325mg the efficacy of the therapy 
improved significantly in this subgroup as well. 5µM and 10µM ADP promoted platelet 
aggregation equivalent to that observed in the control population in about one quarter of 
the thienopyridine treated subjects. We can note that the ratio of ineffective medication 
was as low as 9% in case of a combination therapy (Table 3.3.2). 
 
Table 3.3.2: The ratio of drug insensitive platelet aggregation revealed in case of ASA, 
ticlopidine (TIC), clopidogrel (CLP) and combination (Comb) therapy in the total 
population and in each of the subgroups. 
Subgroups Resistance to antiplatelet drugs 
 ASA 100 ASA 200 ASA 325 TIC 500 CLP 75 COMB 
Subgroup I (%) 30 33 24 0 18 9 
Subgroup II (%) 23 10 0 10 7 0 
Subgroup III (%) 46 39 18 26 24 9 
Subgroup IV (%) 43 28 23 23 21 13 
Subgroup V (%) 48 39 31 36 25 13 
Total population 40 26 21 22 20 7 
 
 847 subjects in subgroup IV were on ASA medication with the low daily dose of 
the drug representing the most frequently administered medication in this subgroup as 
well.  Aspirin was found to be ineffective in 39% of this population on average with an 
obvious association between the applied daily drug dose and the efficacy of the 
treatment. Despite the regular administration of 500mg ticlopidine or 75mg clopidogrel, 
persistent platelet activation was demonstrated in 22% of subjects. Combination therapy 
was rare in this subgroup, and as expected, its efficacy was superior to that of any 
antiplatelet drugs applied in monotherapy (Table 3.3.2). 
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 A great majority (85%) of patients seen from family practices (subgroup V) 
received ASA monotherapy. The ratio of ineffective antiplatelet medication was the 
highest in this subgroup reaching as high as 43%. An ADP receptor blocker medication 
was rarely administered, the prevalence of inappropriate drug effect reached as high as 
29%. Merely some of the enrolled subjects were on a combination therapy, although the 
occurrence of individuals with drug insensitive platelet aggregation was the highest 
within this subgroup (Table 3.3.2). 
 
3.3.2 Patient follow-up 
Following the initial laboratory visit, we monitored the antiplatelet therapy of 
our cooperative patients for up to 2 years. Furthermore, we investigated whether the 
prolonged administration of a fixed daily dose of ASA or thienopyridine derivate 
provokes reduced sensitivity to these agents. The aggregometric responses to collagen 
and epinephrine decreased in 44% of patients on a daily dose of 100mg ASA throughout 
the follow-up period with the maximum aggregation indices reaching similar values 
observed in the control population. Of these subjects, 45% and 37% converted to 
non-responder within the initial six or twelve months of the study, respectively 
(Figure 3.3.2). Following an improper aggregometry result with 100mg ASA, the daily 
drug dose was increased up to 325mg. The test performed within 30 days subsequent to 
the therapy adjustment revealed appropriate laboratory effect in 79% of previously ASA 
insensitive subjects. Similar, although less prominent phenomena could be noted 
regarding the aspirin sensitivity of patients on a high daily dose of the drug; 25% of 
them converted to non-responder over the entire follow-up period with the 12 months 
visit revealing therapy insensitive platelet aggregation in most cases (Figure 3.3.2).  
If 325mg/day aspirin did not diminish collagen and epinephrine induced platelet 
aggregation, the administration of a thienopyridine derivate was proposed. The regular 
daily doses of ticlopidine and clopidogrel provided efficient platelet inhibition in 89% of 
previously ASA non-responder patients when tested one month following the therapy 
modification. It is important to note that our assay did not reveal any remarkable change 
regarding the antiplatelet efficacy of either ticlopidine or clopidogrel throughout the 
entire follow-up period.  
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Figure 3.3.2: The ratio of newly discovered aspirin non-responder patients at each visit 
(bar graphs). The solid lines represent the cumulative ratio of subjects with ASA 
insensitive platelet aggregation revealed throughout the follow-up.  
 
3.3.3 Prospective study 
 As a pilot, prospective study we addressed the possible association between the 
antiplatelet efficacy of ASA (including all aspirin doses) and thienopyridine derivates 
estimated by platelet aggregometry and the long-term clinical outcome (24 months). 
Despite the regular administration of antiplatelet medications, the ratio of inappropriate 
laboratory tests reached as high as 50% among individuals developing an ischemic 
event (acute coronary syndrome, stroke or TIA) within the study period. In contrast, 
therapy resistant platelet aggregation could be revealed in merely 30% of the population 
without a negative clinical outcome. Despite the low number of enrolled individuals, our 
results demonstrate a significant relative risk reduction in patients with an appropriate 
aggregometry test (p<0.001). We should note that no remarkable discrepancy could be 
detected between the two populations regarding the indication of the therapy and the 
prescribed antiplatelet medications. This observation might reveal a considerable 
association between the ex vivo aggregometry results and the long-term clinical 
effectiveness of secondary prevention. 
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3.4 Discussion 
 
 Platelets have a well-identified, critical role in the development of 
cardiovascular diseases including coronary artery thrombosis, stroke and peripheral 
vascular diseases [130]. In case of an atherosclerotic plaque disruption blood might be 
exposed to subendothelial structures within the damaged vessel wall. As a consequence, 
aberrant and excessive platelet aggregation occurs leading to occlusive thrombi 
formation [71].  
 Antiplatelet agents were proved to reduce the incidence of serious vascular 
events throughout the secondary prevention [3]. Several drugs with improved 
effectiveness have been developed to influence discrete mechanisms of clot formation. 
The cyclooxygenase inhibitor ASA has been the standard antiplatelet agent for decades; 
however, several patients develop recurrent atherothrombotic events despite the regular 
administration of aspirin during the long-term follow-up. Possible mechanisms involved 
in ASA resistance have been summarized previously [16]. Increasing the daily drug 
dose to 325mg might be beneficial; however, these subjects will certainly not be 
resistant to the side effects of the high aspirin dose [3]. Thienopyridine derivates are 
alternative antiplatelet agents employed in the secondary prevention of cardio- and 
cerebrovascular diseases; severe side effects are also less frequent. In contrast with 
primary expectations though, recent studies confirm the occurrence of thienopyridine 
non-responder patients in the general population [168]. Considering the number of 
agonists leading to platelet activation, the combination of aspirin and a thienopyridine 
derivate, or pharmaceutical interventions blocking the final common pathway of clot 
formation - the GP IIb/IIIa receptors - represent the most effective antiplatelet 
medications available today [116,153]. 
 In the first part of the present study we evaluated the efficacy of routine 
antiplatelet medication in the general population. Inappropriate platelet inhibition was 
revealed in approximately one third of the aspirin-treated subjects with the highest ratio 
among patients on a low daily drug dose. We can note an obvious association between 
the applied ASA dose and the inhibition of platelet function ex vivo. This finding was 
also verified in an earlier trial, where numerous hemorheological parameters and platelet 
aggregation were monitored for a year in subjects with previous ACS [95]. 21% of the 
study population was on a thienopyridine derivate with the indication of ASA 
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non-response or drug intolerance. Despite the improper drug effect revealed in some 
subjects - confirming the existence of thienopyridine non-response -, ticlopidine and 
clopidogrel provided appropriate platelet inhibition for 79% of these high-risk patients. 
The observed resistance to thienopyridine derivates might be explained by the great 
variability in body mass indices, inappropriate compliance or by the individual 
differences in the metabolic activity of the liver enzymes also affected by certain 
medications employed throughout the secondary prevention. The combination of ASA 
and a thienopyridine derivate proved to be effective in a great majority of the 
population. Although this therapy is obligatory following percutaneous coronary 
interventions (PCI) and - as anticipated - the most effective way to inhibit platelet 
function, serious and undesirable side effects may occur [149]. Applying the lowest, but 
still effective daily drug doses might help to diminish the risk of major bleeding 
disorders in these subjects. Further studies are required to elucidate possible drug 
interactions interfering with an effective and safe antiplatelet therapy. 
 Following the initial data analysis we assessed the efficacy of routine antiplatelet 
medication in each subgroup separately. The lowest ratio of ASA non-responder 
patients was discovered in subgroup II followed by subgroup I. These subjects with 
previous ACS were regularly followed-up by a specialist in cardiology; their 
compliance is thought to be appropriate. Our assumption was also supported by the 
software of the platelet aggregometer estimating a compliance value over 92%. A higher 
ratio of ineffective ASA therapy was revealed in subgroup IV, subgroup III and 
subgroup V that might be explained - at least in part - by the irregular or even absent 
medical visits resulting in their slightly lower compliance. Detecting these subjects with 
better reporting, by measuring the urinary 11-dehydrothromboxane B2 level or by the 
routine use of arachidonic acid in platelet aggregometry tests might help to reduce the 
number of non-compliant patients and thus ASA non-response. Our laboratory results 
revealed several individuals showing reduced sensitivity to ticlopidine and clopidogrel 
in each subgroup. In accordance with our findings with aspirin, the ratio of ineffective 
thienopyridine therapy was slightly higher in subgroups III, IV and V than among 
subjects participating in a strict follow-up program. These results further confirm the 
importance of platelet function testing and the value of regular medical controls 
throughout the secondary prevention. 
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In the following part of our study the effect of long-term ASA and 
thienopyridine administration was assessed. The inhibition of platelet function achieved 
by a fixed daily dose of aspirin progressively decreased over the follow-up period in a 
remarkable number of subjects. The observed decline of platelet sensitivity was 
dependent on the daily drug dose; the number of patients converted to non-responder 
was significantly higher among subjects on 100mg/day ASA than in case of higher drug 
doses. In contrast with these findings, the antiplatelet efficacy of ticlopidine and 
clopidogrel was found to be persistent in 99% of the population for the entire period of 
24 months. Our findings further suggest that - based on the laboratory results - 
increasing the daily aspirin dose within the recommended range of 75-325mg might be 
beneficial for a large patient population. However, given the increasing rate of 
morbidity related to side effects, currently no clinical indication exists for the routine 
use of higher daily ASA doses throughout the secondary prevention of cardiovascular 
diseases [3]. It is also important to note that platelets from the great majority of 
previously aspirin non-responder subjects showed proper sensitivity when administering 
a thienopyridine derivate. 
In the second part of the study we attempted to substantiate a linkage between 
the laboratory effectiveness of routine antiplatelet therapy and the long-term prevalence 
of atherothrombotic events. Our preliminary data reveal a strong positive correlation 
between the individual responsiveness to ASA or thienopyridine derivates and the 
occurrence of undesirable clinical events.  Improving and monitoring the efficacy of 
antiplatelet medication might help to reduce the prevalence of recurrent ischemic 
episodes by 40% among high-risk subjects. These results suggest the importance of 
platelet function tests and the absolute value of regular medical control throughout the 
secondary prevention. However, further prospective studies are required to confirm our 
initial findings in a large patient population. 
 
 
3.5 Study limitations 
 
 A large number of patients participated in the present, non-randomized study. 
Two independent medical doctors evaluated the platelet aggregometry results in each 
case. They were blinded to the antiplatelet medication as well as the diagnosis and the 
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possible adverse clinical events. Patient compliance was assessed by detailed 
questionnaires and the aggregometer software at each visit; although direct laboratory 
measurements were not employed to control the validity of these data.  
 
 
3.6 Conclusions 
 
In accordance with previous reports, our results indicate that the standard daily 
doses of aspirin do not develop appropriate antiplatelet efficacy in a significant number 
of patients.  This study also confirms the occurrence of thienopyridine non-responders 
examining a large patient population for the first time. Detecting subjects with reduced 
platelet sensitivity and adjusting their medication individually might help to reduce the 
occurrence of further ischemic events as well as the prevalence of serious side effects. 
Appreciating platelets’ role in the development and progression of ischemic vascular 
diseases, individually adjusted antiplatelet therapy might improve the value of 
secondary prevention. 
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4. INHIBITION OF ADP-EVOKED PLATELET AGGREGATION BY 
SELECTED POLY(ADP-RIBOSE) POLYMERASE INHIBITORS 
 
 
4.1 Introduction 
 
Poly(ADP-ribose) polymerase (PARP) is a 116kDa Zn2+-finger nuclear protein 
present exclusively in eukaryote cells. Thirteen subtypes of the enzyme have been 
identified to date with PARP-1 discovered initially and examined the most extensively. 
Its biological activity is dramatically and transiently induced by DNA damage, 
especially caused by reactive oxygen species (ROS). In fact, a direct correlation 
between the activity of the enzyme and the extent and number of single-strand DNA 
breaks has been documented previously [117]. Upon binding to the damaged DNA, 
PARP forms homodimers and catalyzes the cleavage of cellular NAD+ to ADP-ribose 
and nicotinamide units. The enzyme utilizes multiple, occasionally over 200 of these 
ADP-ribose units to synthesize and covalently attach poly(ADP-ribose) chains to 
various nuclear acceptor proteins [22,163]. As poly(ADP-ribosylation) confers a highly 
negative charge, it exerts a dramatic effect on the function of target proteins. 
 Although the exact range of the physiological roles of PARP has not been 
completely elucidated yet, it certainly involves nine main functions: 
• It has been implicated in DNA repair and the maintenance of genomic integrity 
[21,33,34]. This function is indicated by delayed DNA base-excision repair and 
by the high frequency of sister chromatid exchange in PARP-1 deficient cells 
exposed to ionizing radiation or treated with alkylating agents [34]. 
• PARP-1 regulates the production of various inflammatory mediators, such as the 
inducible nitric oxide synthase (iNOS) or intercellular adhesion molecule-1 
[83,176]. NFκB is the key transcription factor controlling the synthesis of these 
proteins, and PARP has been shown to act as a co-activator in the 
NFκB-mediated transcriptions [108]. 
• The enzyme has a major role regulating replication and differentiation. This 
function is supported by the observation that poly(ADP-ribose) metabolism is 
accelerated in the nuclei of proliferating cells [72]. Furthermore, several 
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replication factors as well as the centromere have been shown to serve as 
substrates for PARP [135]. 
• Poly(ADP-ribosylation) has been implicated in the regulation of telomerase 
activity. Although results from previous studies are controversial, the enzyme 
might have an important role in maintaining telomere length [134,138]. 
• The activation of PARP has been proposed to represent a cell-elimination 
pathway allowing the removal of critically damaged cells. Severe genotoxic 
noxa might lead to the overactivation of the enzyme thus the depletion of NAD+ 
and ATP leading to necrotic cell death [10,162]. 
• Poly(ADP-ribose) polymers might be used as an emergency source of energy to 
synthesize ATP [96]. 
• Poly(ADP-ribose) might serve as a signal for protein degradation in oxidatively 
damaged cells [26,160]. 
• Poly(ADP-ribose) polymers can establish non-covalent bonds with specific sites 
of various proteins (e.g., histones, p53) and thus modify their function [119]. 
These polymers are formed as a result of the poly(ADP-ribose) glycohydrolase  
activity [32]. 
• Poly(ADP-ribosylation) might be involved in the regulation of cytoskeletal 
organization. The overexpression of PARP-1 has been proved to disrupt the 
structure of the cytoskeletal F-actin molecules thus leading to aberrant cell and 
tissue morphology [159]. 
 
 As detailed above, PARP plays a pivotal role in maintaining genomic integrity 
through the modulation of cellular responses upon DNA injury. In contrast, permanently 
high ROS concentrations present under various clinical and experimental conditions 
(i.e., myocardial and brain ischemia-reperfusion, diabetes or anticancer therapy) might 
cause an extensive DNA damage leading to excessive PARP activation (Figure 4.1.1). 
The ensuing intracellular NAD+ depletion compromises mitochondrial substrate 
oxidation as well as ATP production culminating in necrotic cell death due to energy 
depletion [69,152]. Recognizing the biological function of PARP led to the hypotheses 
that inhibiting the enzyme can partially prevent ROS induced cell damages [102,131]. 
 Intensive research has been devoted in the last decade to synthesize small 
molecules that can effectively bind to the PARP enzyme thus blocking its activity. 
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Numerous experimental PARP inhibitor agents have been proved to be successful in 
limiting ischemia-reperfusion injury of the cardiac muscle and brain tissue. They were 
effective in delaying the progressive functional impairment in chronic heart failure and 
the development of streptozotocin-induced diabetes. Also, these molecules reduced the 
occurrence of acute photodamage, endothelial dysfunction and the extensive tissue 
damage observed in shock [163,36,45,61,109,110,111,118,146,145,173]. Knockout 
animal models have further demonstrated that disrupting the PARP gene increases cell 
tolerance against oxidative damages [42,65]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1.1: Deleterious effects of reactive oxygen species (ROS) and the 
mechanisms of cell protection provided by PARP inhibitor molecules.  
 
As discussed previously, hemorheological parameters might be significantly 
altered by reactive oxygen species. Also, oxidative stress triggered by ischemia-
reperfusion in patients with ACS or in subjects following percutaneous coronary 
interventions may result in a remarkable thrombocyte activation leading to thrombosis 
and subsequent re-occlusion [49,68,79]. The role of ADP is inevitable and widely 
accepted in provoking and amplifying platelet aggregation both under physiological 
circumstances and the pathological conditions mentioned above. Furthermore, it is a 
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commonly applied agonist in laboratory tests so as to induce platelet aggregation. It is 
important to note that the structure of the most potent PARP inhibitors resembles to that 
of the adenine moiety of ADP-ribose and, thus, can interact with the substrate-binding 
site of the enzyme [22,163]. From this perspective it is tempting to speculate that ADP-, 
or adenine-mimicking agents might also bind to the ADP receptors present on platelets’ 
surface - acting as competitive antagonists - and thus inhibit their aggregation. This 
novel feature of PARP inhibitors would further extend the variety of recently available 
antiplatelet drugs employed throughout the secondary prevention of occlusive vascular 
diseases. Especially, since agents blocking thrombogenic platelet functions have been 
proved to reduce significantly the risk of recurrent ACS and stroke over long term 
follow-up [3]. 
 Based upon the aforementioned context, we tested the hypothesis that 
poly(ADP-ribose) polymerase inhibitors with adenine-like molecular structure can 
impede platelet aggregation. Since localized thrombocyte activation, adhesion and 
aggregation contribute to the development and progression of myocardial ischemia, 
efforts to optimize the treatment of cardiac ischemia-reperfusion injuries would 
welcome novel agents that render protection for cardiomyocytes, microcirculation as 
well as blood cells at the same time. Our results demonstrate for the first time that 
selected PARP inhibitors may fulfill this role by delivering myocardial cell protection as 
well as by exerting beneficial effects on tissue perfusion - via blocking platelet 
aggregation induced by ADP - under conditions of reduced coronary flow [163,61]. 
 
 
4.2 Materials and Methods 
 
4.2.1 Chemicals and reagents 
Acetyl salicylic acid was a gift from Sanofi-Synthelabo Ltd. (Le Plessis-
Robinson, France), eptifibatide was purchased from Schering-Plough Ltd. (New York, 
USA). 4-hydroxyquinazoline and 2-mercapto-4(3H)-quinazolinone were obtained from 
Sigma-Aldrich Chemie Ltd. (Steinheim, Germany). HO-3089 was synthesized at the 
Institute of Organic and Medicinal Chemistry, University of Pecs, Medical School. The 
molecular structures of PARP inhibitors utilized in the present study are demonstrated 
on Figure 4.2.1. ADP, collagen, and epinephrine were purchased from Carat Ltd. 
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(Budapest, Hungary). Sodium-heparin was obtained from Biochemie Ltd. (Vienna, 
Austria). All other reagents were used at the highest purity commercially available. 
 
 
 
 
 
 
 
 
 
Figure 4.2.1: Chemical structure of the examined poly(ADP-ribose) 
polymerase inhibitors: 4-hydroxyquinazoline, 2-mercapto-4(3H)-
quinazolinone and HO-3089. 
 
4.2.2 Oxidative challenge of cultured cardiomyocytes 
 H9c2 cardiomyocytes, a clonal line derived from embryonic rat heart, were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 
fetal calf serum and 2mM pyruvate in a humidified atmosphere of 95% air and 5% CO2 
at 37ºC. Before reaching confluence, the cells were split, plated at low density in culture 
dishes (approx. 2×104 cell/well) and cultured for 24 hours. Cardiomyocytes were then 
incubated without (negative control) and with 1mM hydrogen peroxide for three hours 
either untreated (positive control) or treated with 4-hydroxyquinazoline, 2-mercapto-
4(3H)-quinazolinone (both in 5, 10, 20, 50, 100, 500, 1000, and 1500µM), or HO-3089 
(in 0.1, 0.5, 1, 2, 10, 20, 50, 100, and 500µM). At the end of the incubation period cell 
survival was determined by the MTT assay as the percentage of survival in negative 
control samples. 
 
4.2.3 Test validation and the antiplatelet effect of PARP inhibitors 
Venous blood samples were drawn from healthy adult donors into Vacutainer® 
tubes containing trisodium citrate (3.8%). An experimental PARP inhibitor or a 
well-known antiplatelet drug (ASA or eptifibatide) - all dissolved and diluted in distilled 
water - was added to the tubes at various final concentrations: 4-hydroxyquinazoline, 
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2-mercapto-4(3H)-quinazolinone (both in 100, 500, 1000, and 1500μM) and HO-3089 
(in 10, 20, 50, 100, and 500μM). ASA (in 0.25, 0.5, 1, 2, 7, 20, and 70μM) and 
eptifibatide (in 100, 200, 300, 400, 500, and 1000ng/ml) served as control drugs. Equal 
volume of distilled water was added to the control tubes. Samples were incubated and 
continuously mixed at 37°C for 20 minutes to ensure optimal drug effect. 
 
4.2.4 The effect of incremental ADP concentrations 
Following the incubation period, PPP and PRP were prepared according to the 
method detailed previously in chapter 3.2.4. ADP (final concentrations: 5 and 10μM), 
collagen (2μg/ml) and epinephrine (10μM) were utilized as inductors throughout the 
experiment. Aggregation curves were monitored up to 10 minutes using the Carat TX-4 
optical platelet aggregometer (Figure 3.2.2). We compared the maximal aggregation 
indices of the samples to that of control in each PARP-inhibitor concentration. All 
measurements were carried out within 2 hours following venipuncture and were 
repeated 15 times using blood samples from different individuals for every applied 
compound concentration. It is well documented that optical aggregometry is not suitable 
to assess platelet aggregation in case of any hemolysis. Therefore, the desensitization of 
platelet receptors by ADP released from damaged erythrocytes could be excluded. 
 
4.2.5 Heparin induced platelet hypersensitivity 
In a subsequent experiment we evaluated the antiaggregatory effect of PARP 
inhibitors on thrombocytes stimulated with increasing ADP concentrations. Initially, 
platelet aggregation was almost completely blocked by adding high concentrations of 
4-hydroxyquinazoline, 2-mercapto-4(3H)-quinazolinone or HO-3089 to the samples 
(2000, 2000, and 1000μM, respectively). Following the twenty-minute incubation 
period, platelet aggregation was induced with ADP applied in various final 
concentrations (2, 5, 10, 15, 20, and 40μM). We compared the extent of maximum 
aggregation to the control measurement in each case. 
It is well documented that heparin enhances platelet aggregation in vivo, and 
also when stimulated by any of the inductors in vitro [97]. In the following part of the 
study we evaluated the hypotheses that PARP inhibitors can effectively antagonize 
heparin-induced platelet hyperreactivity. Besides the experimental molecule, 
sodium-heparin (final concentration: 5U/ml) was also added to the samples prior to the 
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twenty-minute incubation period. Sample preparation and testing were performed 
according to the method described previously with the exception that platelets were 
stimulated by incremental ADP concentrations: 0.5, 1, 2.5, 5 and 10μM. The extent of 
maximum aggregation was compared to that of control (sample incubated with the same 
amount of heparin but without any PARP inhibitor) in each case. 
 
4.2.6 Statistical analysis 
 Data are presented as means±SEM. Samples were compared to the control 
values using the Students’ t test. 
 
 
4.3 Results 
 
4.3.1 Effect of PARP inhibitors on the survival of cardiomyocytes during oxidative insult 
 Following the three-hour incubation period of H9c2 cardiomyocytes in the 
presence of 1mM hydrogen peroxide, merely 44±6% of the cells survived. 
4-hydroxyquinazoline and 2-mercapto-4(3H)-quinazolinone could not significantly 
improve the survival of the cells in the concentration range of 5-50µM. Nevertheless, in 
100µM and above, 4-hydroxyquinazoline and 2-mercapto-4(3H)-quinazolinone 
protected the cells significantly when compared to the untreated samples (p<0.01). In 
the meantime, all the examined concentrations of HO-3089 (0.1-500µM) promoted the 
survival of H9c2 cells remarkably (p<0.01) (Table 4.3.1, Figure 4.3.1). 
 
4.3.2 In vitro test validation 
Two clinically used antiplatelet agents were utilized at the first stage of our study 
to validate the in vitro measurements. As anticipated, acetyl salicylic acid decreased 
collagen- and epinephrine-induced platelet aggregation in a concentration-dependent 
manner. Significant inhibitory effect could be detected as of 1µg/ml up to the entire 
examined concentration range (Figure 4.3.2). An in vitro concentration of 2µg/ml and 
7µg/ml correspond to the eventual serum concentrations observed upon the oral 
administration of 100mg and 325mg ASA/day, respectively [115,113]. At the same 
time, acetyl salicylic acid had merely minimal impact on ADP-induced platelet 
aggregation. 
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Figure 4.3.1: Effect of PARP inhibitors on the survival of H9c2 cardiomyocytes during 
three-hour hydrogen peroxide-induced (1mM) oxidative stress. Survival rates are 
expressed as the percentage of the cell count in negative (untreated) controls 
(mean±SEM) (*p<0.01). Positive control: survival in the presence of 1mM H2O2 
without any PARP inhibitor. All conditions were carried out in quadruplicate. 
 
Table 4.3.1: IC50 values of the experimental PARP inhibitors for H9c2 cardiomyocyte 
survival and for remarkable antiplatelet activity in the presence of 5µM or 10µM ADP. 
Hydroxyquinazoline Mercaptoquinazolinone HO-3089 
IC50 values considering the survival of cardiomyocytes 
92µM 96µM 35nM 
IC50 values of antiplatelet activity in the presence of 5µM ADP 
1720µM 1310µM 185µM 
IC50 values of antiplatelet activity in the presence of 10µM ADP 
3065µM 2380µM 432µM 
  40
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.2: Dose-response curves of human platelets obtained when using ADP (5μM 
and 10μM), collagen (2μg/ml) and epinephrine (10μM) as agonists in the presence of 
increasing acetyl salicylic acid concentrations. 
 
 The inhibitory effect of eptifibatide was proportional to the applied drug 
concentration and could totally block platelet aggregation stimulated by any of the 
agonists in a concentration as low as 400ng/ml, well below its normal in vivo serum 
level (approximately 1000ng/ml during continuous intravenous administration) [31]. By 
blocking the GP IIb/IIIa platelet fibrinogen receptors, eptifibatide completely abolishes 
platelet aggregation independent of the type of activation used (Figure 4.3.3). 
 
4.3.3 Effect of PARP inhibitors on ADP-, collagen-, and epinephrine-induced platelet 
aggregation 
The commercially available PARP inhibitors, 4-hydroxyquinazoline and 
2-mercapto-4(3H)-quinazolinone markedly decreased platelet aggregation induced by 
either 5 or 10µM ADP at a final concentration of 500µM. At the same time, the 
experimental molecule, HO-3089 provided a remarkable inhibition even when applied 
at 20µM (Figures 4.3.4 and 4.3.5). Each compound exerted an incremental antiplatelet 
efficacy as the administered concentration increased and could markedly reduce the 
effect of ADP when applied at higher concentrations. While 4-hydroxyquinazoline did 
not affect significantly collagen- (2µg/ml) and epinephrine- (10µM) induced platelet 
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aggregation, 2-mercapto-4(3H)-quinazolinone and HO-3089 were able to impede it, but 
merely at the highest examined concentrations (1500µM and 500µM, respectively) (data 
not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.3: Dose-response curves of human platelets obtained when using ADP (5μM 
and 10μM), collagen (2μg/ml) and epinephrine (10μM) as agonists in the presence of 
increasing concentrations of eptifibatide. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.4: Response of human platelets to 5μM ADP as agonist in the presence of 
increasing concentrations of PARP inhibitors (mean±SEM) (†p<0.05, *p<0.01). All 
experiments were repeated 15 times. 
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Figure 4.3.5: Response of human platelets to 10μM ADP as agonist in the presence of 
increasing concentrations of PARP inhibitors (mean±SEM) (†p<0.05, *p<0.01). All 
experiments were repeated 15 times. 
 
4.3.4 Antiplatelet activity of PARP inhibitors in the presence of incremental ADP 
concentrations 
As anticipated, we found PARP inhibitors to primarily antagonize ADP-induced 
platelet aggregation in our experiments. Considering the fact, that a particular PARP 
inhibitor concentration had reduced impact on platelets when higher levels of ADP 
(5µM vs. 10µM) were applied, the dependence of their antiplatelet efficacy on the 
applied inductor concentration was evaluated. As we can note on Figure 4.3.6, 
maximum aggregation indices achieved by 5µM and 10µM ADP are essentially the 
same in case of control measurements as 5µM ADP is sufficient to induce a complete 
aggregatory response. In contrast, platelet reactions accomplished with the same 
agonists were reduced significantly in the presence of PARP inhibitors. The figure also 
demonstrates that parallel to the increasing ADP concentrations, the hindrance of 
HO-3089 on platelet aggregation waned and finally disappeared at 40µM. Similar 
phenomena were documented when applying any of the other two commercially 
available PARP inhibitors (data not shown). The level of maximum aggregation in case 
of the highest ADP concentration - despite the presence of high PARP inhibitor 
concentrations - was found to be similar to that of control measurements. 
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Figure 4.3.6: Representative response curves of human platelets using incremental 
concentrations of ADP (2-40μM) in the presence of HO-3089 (1000μM, a concentration 
that caused complete blockade of aggregation at the lowest ADP concentration). Similar 
phenomenon was observed with the application of 4-hydroxyquinazoline or 2-mercapto-
4(3H)-quinazolinone (both in 2000μM, a concentration which caused complete 
blockade of aggregation) (data not shown). All experiments were repeated 15 times 
 
4.3.5 Heparin-induced platelet hypersensitivity and the efficacy of PARP inhibitors 
In accordance with previous studies, our findings confirmed that human platelets 
show hypersensitivity to ADP in the presence of unfractionated heparin. As expected, 
ADP stimulated platelet aggregation in a dose dependent manner, but the concentration 
required to initiate the process was significantly lower than in the absence of heparin. 
Furthermore, an almost complete aggregation response was recorded even when 
applying the agonist well below its commonly utilized concentration (1µM vs. 10µM). 
Most importantly, this heparin-evoked sensitization of platelets was markedly reduced 
in the presence of the experimental PARP inhibitor molecules (Figure 4.3.7). 
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Figure 4.3.7: The mean response of human heparin-sensitized platelets (5U/ml) to 
increasing concentrations of ADP (0.5-10μM) in the presence of high concentrations of 
4-hydroxyquinazoline, 2-mercapto-4(3H)-quinazolinone or HO-3089 (2000, 2000, 
1000μM, respectively). 
 
 
4.4 Discussion 
 
Pathological platelet aggregation is widely accepted to play an indispensable step 
in the pathogenesis of cardio- and cerebrovascular diseases and antiplatelet therapy has 
become a useful means of preventing and treating atherothrombotic events [136]. 
Numerous compounds have been developed to interfere with clot formation either at a 
receptorial (GP IIb/IIIa blockers, thienopyridine derivates) or enzymatic level (ASA), 
although they do not exert any additional impact on cell survival. In our in vitro study 
we evaluated the effect of various PARP inhibitors on platelet sensitivity in autologous 
platelet-rich plasma. 
Previous studies demonstrated that poly(ADP-ribose) polymerase inhibitors can 
exert remarkable protection in experimental models of cardiac and brain ischemia-
reperfusion, AZT- and anticancer agent-induced cardiomyopathy, ultraviolet 
radiation-induced skin lesion, various forms of shock, chronic heart failure, diabetic 
endothelial dysfunction, and diabetes [163,36,45,110,111,118,145,61]. The inhibition of 
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the PARP enzyme contributes to the preservation of intracellular nicotinamide adenine 
dinucleotide and adenosine triphosphate pools in oxidatively challenged cells and 
tissues. Due to their structural resemblance, the most efficacious PARP inhibitors can 
compete with ADP-ribose (natural substrate of PARP) for binding to the enzyme 
[163,22]. This obvious similarity raised the possibility that some PARP inhibitors may 
also bind to and thus block the ADP receptors present on platelets surface. We tested 
our hypothesis by utilizing three different experimental molecules that have been shown 
to promote the survival of H9c2 cardiomyocytes exposed to hydrogen peroxide-induced 
oxidative insult. In this widely used setting of oxidative stress, 4-hydroxyquinazoline 
(IC50 for PARP enzyme inhibition: 7μM), 2-mercapto-4(3H)-quinazolinone 
(IC50=35μM), and HO-3089 (IC50=46nM) protected the cardiomyocytes in a 
concentration of 100, 100, and 0.1µM, respectively, and above. These data are also in 
accordance with the results obtained in an isolated heart perfusion system, where 
4-hydroxyquinazoline and 2-mercapto-4(3H)-quinazolinone could preserve myocardial 
high-energy phosphate levels during ischemia-reperfusion cycle when applied in a 
concentration of 100µM [61]. HO-3089 also promoted significantly the recovery of 
high-energy phosphate intermediates tested in the same system, even in a much lower 
concentration (10µM) [82]. Consequently, these PARP inhibitors indeed render 
protection for oxidatively challenged myocardial cells. 
 Our initial findings with well-known, widely administered antiplatelet agents 
validated our in vitro method for the investigation of experimental molecules using the 
same model. As expected, ASA decreased the collagen- and epinephrine-induced 
platelet aggregation in a concentration dependent manner, while eptifibatide completely 
blocked the aggregation - well below its in vivo serum concentration - stimulated by any 
of the agonists. 
All three PARP inhibitors exerted marked antiplatelet activity in our in vitro 
model when ADP was employed as the agonist. However, on a molar basis HO-3089 
had superior platelet inhibitory efficacy (significant inhibition could be observed even at 
20µM) over 4-hydroxyquinazoline and 2-mercapto-4(3H)-quinazolinone (remarkable 
antiplatelet effect at 500µM and above). We can note an obvious inverse correlation 
between the applied dose of the compounds and the platelet sensitivity to ADP. 
Although the concentrations required to abolish platelet aggregation completely proved 
to be significantly higher than that of delivering protection in case of the H9c2 cell 
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culture by inhibiting the PARP enzyme. Considering the relevance of oxidative 
stress-induced thrombocyte activation under various pathological conditions, even 
partial hindrance of platelet function attained by lower serum concentrations of PARP 
inhibitors might have an additional beneficial effect upon tissue ischemia-reperfusion. 
The observed antiplatelet efficacy of the tested PARP inhibitors seems to be 
specific on ADP receptors. 4-hydroxyquinazoline did not have any effect on either 
collagen- (2µg/ml) or epinephrine- (10µM) induced platelet aggregation and 
2-mercapto-4(3H)-quinazolinone and HO-3089 were able to impede it only at the 
highest examined concentrations (data not shown). 
 In order to elucidate the hypothetical mechanism regarding the antiplatelet 
activity of PARP inhibitors, we applied incremental amounts of ADP so as to induce 
platelet aggregation. In accordance with our initial theory, increasing concentrations of 
ADP gradually neutralized the antiplatelet properties of the selected PARP inhibitor 
molecules with maximal aggregation indices reaching similar values to that of untreated 
samples when applying ADP at 40µM. This observation might confirm an eventual 
competitive antagonism as the possible underlying mechanism behind the antiplatelet 
properties of PARP inhibitors. As the newly described phenomenon represents a 
receptorial mechanism, it is not surprising that the minimal concentration of the tested 
molecules required to abolish platelet aggregation was higher than that inhibiting the 
PARP enzyme. In addition, all the examined agents were capable of hindering 
thrombocyte aggregation even if those were sensitized to ADP by the pre-administration 
of heparin. These findings suggest that beyond their myocardial protective effect, our 
PARP inhibitor molecules may also be useful in the prevention and treatment of 
occlusive thrombotic events. 
It might be important to note that Vacutainer® tubes containing sodium citrate 
were utilized throughout our experiments. The use of this anticoagulant might be of 
great interest when assessing the antiplatelet efficacy of novel molecules with unknown 
mechanism of action. It is well documented that decreasing the extracellular Ca2+ 
concentrations in vitro might activate platelet thromboxane formation subsequent to the 
stimulation by adrenaline or ADP. As a consequence, a “secondary response” might be 
noted on the recorded aggregation curve. Inhibiting this excessive generation of 
thromboxane A2 subsequent to ADP or epinephrine stimulation may lead to an 
overinterpretation of the antiplatelet efficacy of both thromboxane synthesis inhibitors 
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and thromboxane receptor antagonists [14,164]. It has also been documented previously 
that artificially added sodium citrate might alter the physiological function of the 
GP IIb/IIIa complex enhancing the binding of some antagonists to this receptor [125]. 
According to our present study, PARP inhibitors are thought to compete with ADP to 
occupy its receptor on the platelet surface and this process is thought to arise 
independent of the low extracellular Ca2+ concentrations [60]. In addition - as discussed 
previously - the examined agents did not have any effect on either epinephrine- or 
collagen-induced platelet aggregation confirming that PARP inhibitors are not likely to 
influence platelet thromboxane A2 biosynthesis. We might conclude that the observed 
antiplatelet effect of PARP inhibitors is certainly not influenced significantly by the use 
of sodium citrate as the anticoagulant. 
 
 
4.5 Conclusions 
 
 This is the first report on the ability of certain poly(ADP-ribose) polymerase 
inhibitors to interfere with ADP-induced platelet aggregation. As this agonist has a 
major role in the physiological thrombocyte activation, our findings may be of crucial 
relevance in the eventual future therapeutic applications of PARP inhibitors. Besides 
preserving the cellular energy stores and protecting the functionality of vascular 
endothelial cells, the revealed beneficial “side-effect” of the selected agents may 
contribute to the survival of ischemic tissues by hindering intravascular thrombus 
formation. These results depict an exciting novel feature of selected, ADP- or adenine-
mimicking PARP inhibitors that further adds to our understanding on the future 
therapeutic potential of these molecules. 
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5. AN AUTOMATED CAPILLARY TUBE VISCOMETER: VALIDATION 
STUDIES 
 
 
5.1 Introduction 
  
 The rapidly expanding science of hemorheology concerns the flow properties of 
blood and its relationship to normal and abnormal physiology. As a major determinant 
of microvascular and tissue perfusion, rheology received considerable attention in the 
last decades. Increasing evidence from several investigations indicated marked changes 
in the rheologic behavior of pathologic blood, including elevated whole blood viscosity, 
increased RBC aggregation and more pronounced non-Newtonian flow behavior 
[23,30,75,80,92,124,128].  
 A basic principle of hemorheology relies on the Hagen-Poiseuille equation 
describing the association between the volumetric flow rate through a tube/vessel, 
pressure head, viscosity of the fluid and the diameter and length of the tube/vessel 
(Figure 5.1.1). As we can note, vessel diameter represents the principal determinant of 
blood flow under normal conditions. In contrast, under pathological circumstances such 
as atherosclerosis, whole blood viscosity turns into a dominant factor affecting 
volumetric flow rate. 
    
    
 
 
Figure 5.1.1: Hagen-Poiseuille equation. 
 
 Numerous clinically important laboratory tests have been developed to study 
hemorheological parameters, most notably whole blood viscosity profiles. Identifying 
elevated whole blood viscosity is of clinical importance since it has a predictive value 
for increased resistance to blood flow in the general circulation and for abnormal blood 
flow dynamics in the microcirculation [92,90,91,124,143] that are identified as the 
central pathophysiologic features of several diseases. They further promote and 
contribute to atherosclerotic plaque formation, shear stress damage at the endothelial 
 
ΔP  π  r4 
  8  l  η 
Q =  
Q = volumetric flow rate       r = tube diameter 
ΔP = pressure head        l = tube length 
η = blood viscosity 
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wall and also facilitate plasma protein interaction with the endothelium in post-stenotic 
recirculation zones (Figure 1.1.1). Note that in addition to the well-known conventional 
risk factors, elevated blood and plasma viscosities have been found to be independent 
predictors of initial and recurrent myocardial infarction, stroke and all-cause mortality 
[30]. Furthermore, assessing whole blood viscosity provides essential information in 
various hematological disorders associated with the “hyperviscosity syndrome” and can 
be a useful diagnostic tool to optimize and monitor therapeutic procedures such as 
hemodilution and exchange transfusions [39,81].  
 Numerous viscometers have been developed aiming the accurate measurement of 
whole blood viscosity. Most devices can be classified as rotational or capillary tube 
systems. 
 
5.1.1 Rotational viscometers 
In a rotational viscometer system the fluid sample is sheared in a narrow gap 
between two surfaces, usually one rotating while the other is stationary. The two most 
frequently utilized geometries are the coaxial cylinder (Couette) and the cone-and-plate 
devices (Figure 5.1.2). 
• The inner cycle of a Couette viscometer is often referred as the bob; the external 
one is called the cup. The shear rate is determined by the speed of rotation and 
also the fixed geometrical dimensions. The latter parameter and the torque can 
be utilized to calculate the shear stress. Torque is a product of a rotating force 
and the distance of its action from the centre of rotation [23]; the same torque 
can be a result of a large force acting near, or a small force acting far from the 
centre. Thus, the uniformity of the shear field is of great importance. The 
collection of viscosity data over various shear rates is only possible by repeating 
the measurements at various speeds of the rotating component. The most 
sensitive coaxial cylinder viscometer is the Contraves LS-30 (Contraves AG, 
Zurich, Switzerland). While the cup rotates at preset frequencies covering shear 
rates of 10-3 to 102s-1, the torque required to keep the bob in a steady position is 
measured by an opto-electromagnetic feedback circuit in this device [141]. 
• The common feature of cone-and-plate viscometers is that the fluid is sheared 
within the narrow gap between a flat plate and a cone with low angle (typically 
not exceeding 4º). A nearly uniform shear rate is produced, which is determined 
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by the angle of the gap and also the linear rotational speed of the plate. The most 
reliable, commercially available cone-and-plate device is the Wells-Brookfield 
viscometer (Brookfield Engineering Labs, Middleboro, MA). The cone is 
coupled by a spring to a motor with adjustable rotational speeds. The strain of 
the spring is proportional to the torque exerted on the sample and can be read 
directly on a digital display [167]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1.2: The most widely used rotational viscometer systems: 
Contraves LS-30 (left photo) and Wells-Brookfield (right picture). 
 
 Despite their popularity, rotational viscometers can be subject to artifacts 
limiting their routine clinical applicability. They are associated with denatured protein 
films, surface tensions, RBC sedimentation, limited range of reliability and phase 
separation leading to a cell-poor layer at the torque-measuring element [27,128,23]. 
These difficulties are especially evident when measuring whole blood viscosity at low to 
medium flow rates in order to obtain a shear rate-viscosity profile. Commercially 
available instruments tend to work only over a limited shear rate range, so that 
collecting data over a wide range of physiologically relevant flow rates (to create 
clinically appropriate viscosity profiles) often requires two separate viscometer systems 
and extended periods of time. Furthermore, blood samples have to be removed and the 
test section needs to be cleaned manually following each test posing a potential risk for 
contacting contaminated sample.  
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5.1.2 Capillary tube viscometers 
The principle of capillary tube viscometers relies on the Hagen-Poiseuille 
equation detailed previously (Figure 5.1.1). In order to accurately assess whole blood 
viscosity using these systems, it is inevitable to independently determine the pressure 
drop and flow rate along the cylindrical capillary. The shear stress is zero at the axis of 
the capillary and increases linearly with the distance, reaching its greatest value at the 
tube wall. Thus, it is essential to know the exact dimensions of the capillary in order to 
determinate the functional dependence between the volumetric flow rate and the 
pressure drop due to friction. Also, the sample flow has to be regarded as steady-state, 
isothermal and laminar. Most of the commercially available capillary viscometers 
produce accurate measurements only at a specified, pre-determined shear rate at a time. 
However, for non-Newtonian fluids - since the viscosity varies with shear rate - it is 
vital to repeat the test by varying the pressure in the reservoir tank in order to change the 
flow rate and to obtain physiologically relevant whole blood viscosity-shear rate 
profiles. This makes measurements complicated and extremely time consuming. Other 
common difficulties associated with traditional tube viscometers include their limited 
shear rate range, the “end effect” and the “carry-over” phenomena [23]. “Hevimet 40” is 
the only available capillary viscometer system that is free from most of the difficulties 
mentioned above (Figure 5.1.3). Following the injection of 0.5ml sample into the 
device, blood flow is endorsed by gravity and is monitored continuously using an opto-
electronical system. Shear rate and shear stress are calculated by a computer program 
and viscosity values are determined according to the Casson's principle. 
 
 
 
 
 
 
 
 
 
 
Figure 5.1.3: Hevimet 40 capillary viscometer system. 
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Despite its significant clinical value, whole blood viscosity is not measured 
routinely, principally because of the difficulties mentioned before and the logistical 
complications associated with conventional viscometer systems. To address these 
problems a computerized scanning capillary rheometer (Rheolog™, Rheologics, Inc., 
Exton, PA) was developed to provide fast sample testing and data analysis over a wide 
range of shear rates [24]. The viscometer utilizes a U-shaped disposable assembly 
consisting of a horizontal, pre-calibrated capillary with vertical “riser” tubes at each end 
and a stopcock (Figure 5.1.4).  The geometry of the capillary is the key component of 
the test as it defines the pressure gradient between the riser tubes. Also, its relatively 
large inside diameter (800μm) minimizes the tendency of erythrocytes to move towards 
the center of the tube, leaving a plasma-rich zone at the capillary wall 
(Fahraeus-Lindqvist effect) [44]. A further essential feature of the scanning capillary 
viscometer is the use of optical detectors (CCD sensors and LED arrays) in order to 
accurately assess fluid level variations in the riser tubes every 0.02s. Since 1mm is 
represented by 12 pixels of the sensor, the actual changes of the sample height can be 
determined with an accuracy of 0.083mm. Three milliliter of blood is drawn into a 
Vacutainer® tube and introduced into the device via a standard extension kit. Initially 
the sample is directed into the left vertical tube until it reaches a pre-determined height. 
Then the stopcock rotates and allows the blood to flow through the capillary and into the 
right riser tube. When it fills-up to a certain, lower level as detected by the contact 
image sensor, the stepper motor repositions the stopcock thus isolating the sample 
completely. Following a three second stabilization period the analysis begins as the 
valve turns to a position allowing blood flow from the left vertical tube to the right one 
through the capillary. As the process is driven purely by the pressure gradient created by 
the initially unequal heights of blood in the riser tubes, flow occurs rapidly when the test 
starts and - as a result of the decreasing pressure differential - with gradually lower and 
lower rates as the volumes in the vertical tubes equalize. The pressure drop caused by 
the friction at the capillary can be obtained by continuously monitoring the volume of 
the samples in the riser tubes. This parameter is used to derive the velocity, viscosity 
and yield stress of the sample employing a data reduction algorithm based upon the 
Casson relation between shear rate and shear stress [27,128]. Viscosity results over the 
shear rate range of 1-1500s-1 are graphically available through the computerized 
interface in less than 5 minutes from the introduction of the sample into the device. The 
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scanning capillary viscometer is temperature controlled; all measurements are 
performed at 37ºC. Components are disposable, requiring no blood contact and 
cleaning, further reducing biohazard risk. 
 Previous reports have described the operating principle of the Rheolog™ in 
detail [24] and its application in studies of interindividual variability of whole blood 
viscosity with hydration [165], the effect of low-density lipoproteins on blood viscosity 
[103], and temporal variations of blood viscosity over a 14-day period [166].  To date, 
however, trials specific to validity and reproducibility of the measurements under 
various conditions affecting whole blood viscosity have not been published. The present 
study was thus designed to provide direct comparisons between results obtained by the 
Rheolog™ over a shear rate range of 1-1500s-1 with data collected using cone-and-plate 
and Couette viscometers. Furthermore, the effects of storage time and storage 
temperature on whole blood viscosity were assessed at various shear rates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1.4: Schematic drawing of the disposable assembly employed by 
the Rheolog™ system. The heights of the blood columns are monitored 
continuously via two contact image sensors, thereby providing the pressure 
gradient and flow data used to compute blood viscosity-shear rate results. 
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5.2 Methods 
 
5.2.1 Viscometer systems 
Results from three separate viscometer systems were analyzed in the present 
study. 
1) Wells-Brookfield micro cone-plate viscometer model 1/2RVDTCP-200 
equipped with a 0.8 degree cone and a shear rate range of 75-1500s-1. The cone-plate 
separation was adjusted per the manufacturer’s instruction and the viscometer calibrated 
using Newtonian oils of known viscosity (Cannon Instrument Co, State College, PA). 
One ml of blood was used per test and the sample was allowed to equilibrate to 37°C for 
five minutes at a constant shear rate of 75s-1 (Figure 5.1.2). 
2) Contraves Couette viscometer model LS-30 equipped with a 1T-1T bob and 
cup system (i.e., bob diameter = 11mm, cup diameter = 12mm, gap = 0.5mm). The 
viscometer was calibrated with standard Newtonian oils (Cannon Instrument Co, State 
College, PA) and operated at shear rates of 1.29, 3.23, 8.11, 15.0, 37.7 and 51.2s-1. One 
ml of blood sample was used per test and was allowed to equilibrate to 37°C for five 
minutes at a constant shear rate of 15s-1. Note that at the lower rates of steady shear 
where torque-time phenomena can lead to incorrect torque values, an extrapolation to 
zero time method was used to obtain the correct torque at each shear rate (Figure 5.1.2) 
[28]. 
3) Rheolog™ automated scanning capillary viscometer (Rheologics, Inc, Exton, 
PA). For the present study, all the capillary tubes had an internal diameter of 0.79mm 
and a new assembly was used for each test (Figure 5.1.4). Calibration data for the 
disposables were supplied by the manufacturer. As the automated measurement starts as 
soon as the blood is introduced into the device, the Rheolog™ samples were pre-heated 
to 37°C for five minutes in a water bath immediately prior to testing to assure 
temperature stability. Note that since the Rheolog™ system employs a computer for 
data analysis, it is possible to compute viscosity values at any shear rate within the 
useful range of the instrument (i.e., 1-1500s-1). In the present study, shear rates of 1.29, 
3.23, 8.11, 15.0, 37.7, 51.2, 75, 150, 300, 750, and 1500s-1 were utilized for device 
comparisons and 1, 2, 5, 10, 50, 100, 150, 300, and 1000s-1 were used for 
reproducibility studies. 
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5.2.2 Blood samples 
 Blood samples were drawn by sterile antecubital venipuncture into EDTA 
(1.5mg/ml) vacuum tubes from healthy adult donors. Unless otherwise indicated, 
samples were stored at room temperature (22±1°C) and tested within four hours. The 
study was approved by the Institutional Review Board at the University of Southern 
California. No inclusion criteria were employed for the study and exclusion criteria 
were only investigational drug treatment or recent surgery. Blood and RBC-plasma 
suspension hematocrits were determined using the microhematocrit method 
(i.e., centrifugation at 12000g for 5 minutes). 
 
5.2.3 Reproducibility studies 
 Fifty ml of blood was collected from five healthy volunteers (3 males, 2 females, 
mean age: 31±4 years). Samples were processed via centrifugation (1750g, 10 minutes), 
and then RBC and plasma were recombined to achieve 15-20ml per donor of low and of 
high hematocrit suspensions (27% and 58% on average, respectively). Using the 
Rheolog™, ten replicate measurements in rapid sequence were performed for each low 
and high hematocrit suspension. No direct comparisons were employed with other 
viscometer systems in this part of the study. 
 
5.2.4 Comparison studies 
Comparison studies were conducted using two separate protocols: 
• Measurements performed at native hematocrit: Blood samples were collected 
into three K2EDTA Vacutainer® tubes (5ml each) from 44 apparently healthy 
adult donors (26 males, 18 females, mean age: 37±4 years). One tube was 
utilized for the measurements with the Brookfield and Contraves viscometer 
systems, with the other two used for two consecutive Rheolog™ tests termed 
“Rheolog A” and “Rheolog B”. Each tube was sampled only once for the 
experiments with the scanning capillary rheometer. 
• Measurements performed at adjusted hematocrit values: Six vacuum tubes of 
five ml each were collected from eight subjects (4 males, 4 females, mean age: 
33±2years) in order to prepare low (i.e., less than 30%) and high (i.e., greater 
than 55%) hematocrit suspensions via centrifugation/recombination. The 
viscosity of each suspension was measured once in the Brookfield and Contraves 
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systems and twice using the Rheolog™ device (i.e., “Rheolog A” and “Rheolog 
B” tests). 
 
5.2.5 Storage Studies 
The effects of storage time and storage temperature on whole blood viscosity 
profiles were assessed using the Rheolog™ viscometer in this part of the study. Samples 
were collected from eight healthy subjects (4 males, 4 females, mean age: 30±5years) 
into K2EDTA Vacutainer® tubes. Three tubes from each donor were maintained at room 
temperature (22±1°C) and viscosity was measured at 10 minutes, at 4 and 8 hours 
following venipuncture. Two tubes were incubated in a water bath at 37˚C for 3 or 6 
hours then tested. Five tubes were refrigerated immediately and measurements were 
performed seven hours subsequent to blood draw and on the consecutive four days. 
Except for the tubes stored at 37˚C, all samples were incubated for five minutes at 37˚C 
in a water bath prior to testing. Samples stored at 4˚C were removed from the 
refrigerator 60 minutes before performing the measurements. Note that for all storage 
periods and temperatures, the tubes were maintained in a vertical position and were not 
inverted or mixed until selected for testing.  
 
 
5.3 Results 
 
5.3.1 Reproducibility tests 
Results of reproducibility studies with the Rheolog™ (i.e., ten replicate 
measurements of low and high hematocrit suspensions from five donors) are presented 
in Table 5.3.1. Means, standard deviations (SD) and coefficients of variation [CV] are 
shown for shear rates of 1-1000s-1. Upon the inspection of these results we can note that 
the mean CV levels are within 5% or less, except for the high hematocrit data at 1000s-1 
where the mean CV reached 8%. CV values were independent of shear rate (p>0.2 for 
linear regression of mean CV versus shear rate at either hematocrit), but tended to be 
slightly lower for the high hematocrit suspensions in the range of 5-100s-1. These data 
indicate that the Rheolog™ provided reliable and reproducible viscosity data in all 
donors independent of the hematocrit and shear rate. 
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5.3.2 Comparison studies 
Results of the comparison tests performed between the Rheolog™, Brookfield 
and Contraves viscometers are shown in Figure 5.3.1 and Table 5.3.1. In these studies, 
blood from 44 donors was tested at native hematocrit (mean hematocrit = 41.2%), and 
hematocrit-adjusted suspensions from 8 donors were tested at low and high hematocrit 
values. As anticipated from the results presented in Table 5.3.1, replicate measurements 
with the Rheolog™ indicated very close agreement between the means of the two 
separate tests (i.e., “Rheolog A” and “Rheolog B”): at native hematocrit, the maximum 
difference was 2% at 1.29s-1 that decreased to less than 1% at all other shear rates 
(Table 5.3.2). 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 5.3.1: Comparison of mean blood viscosity data for blood at native hematocrit 
from 44 donors. Contraves results are for shear rates of 1.29 to 51.2s-1 and Brookfield 
data are for 75 to 1500s-1. The Rheolog™ was programmed to provide viscosity data at 
shear rates corresponding to those obtained by the Brookfield and Contraves systems. 
Solid line represents smoothed fit of Rheolog™ data. Error bars indicate +SD for 
Rheolog™ data and -SD for the Brookfield and Contraves results. 
 
Over the shear rate range used for these tests (i.e., 1.29-1500s-1), blood viscosity 
measured with the Rheolog™ compared very favorably with the results obtained with 
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Whole blood viscosity (mPa.s) 
Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 
Shear 
rate (s-1) 
Hct=27% Hct=58% Hct=28% Hct=57% Hct=29% Hct=54% Hct=27% Hct=57% Hct=27% Hct=57%
1 
6.42 
(0.05) 
[0.78] 
42.71 
(2.03) 
[4.76] 
6.38 
(0.04) 
[0.63] 
35.72 
(2.45) 
[6.86] 
6.53 
(0.25) 
[3.83] 
41.34 
(2.04) 
[4.93] 
6.46 
(0.06) 
[0.93] 
39.27 
(2.39) 
[6.09] 
6.60 
(0.22) 
[3.33] 
40.37 
(2.03) 
[5.03] 
2 
5.40 
(0.07) 
[1.29] 
27.69 
(1.05) 
[3.79] 
5.50 
(0.09) 
[1.64] 
23.58 
(1.16) 
[4.92] 
5.47 
(0.22) 
[4.02] 
26.47 
(1.14) 
[4.31] 
5.36 
(0.08) 
[1.49] 
25.33 
(1.33) 
[5.25] 
5.35 
(0.19) 
[3.55] 
26.23 
(0.95) 
[3.62] 
5 
4.56 
(0.16) 
[3.51] 
17.08 
(0.43) 
[2.52] 
4.77 
(0.17) 
[3.56] 
14.92 
(0.39) 
[2.61] 
4.61 
(0.26) 
[5.64] 
16.04 
(0.57) 
[3.55] 
4.47 
(0.18) 
[4.03] 
15.51 
(0.65) 
[4.19] 
4.35 
(0.21) 
[4.83] 
16.23 
(0.31) 
[1.91] 
10 
4.17 
(0.20) 
[4.80] 
12.70 
(0.25) 
[1.97] 
4.42 
(0.20) 
[4.52] 
11.30 
(0.24) 
[2.12] 
4.21 
(0.29) 
[6.89] 
11.77 
(0.36) 
[3.06] 
4.05 
(0.23) 
[5.68] 
11.47 
(0.42) 
[3.66] 
3.88 
(0.23) 
[5.93] 
12.10 
(0.18) 
[1.49] 
50 
3.38 
(0.15) 
[4.44] 
7.87 
(0.20) 
[2.54] 
3.59 
(0.18) 
[5.01] 
7.26 
(0.36) 
[4.96] 
3.39 
(0.19) 
[5.60] 
7.10 
(0.20) 
[2.82] 
3.28 
(0.21) 
[6.40] 
7.08 
(0.28) 
[3.95] 
3.18 
(0.17) 
[5.35] 
7.53  
(0.28) 
[3.72] 
100 
3.04 
(0.10) 
[3.29] 
6.89 
(0.21) 
[3.05] 
3.18 
(0.16) 
[5.03] 
6.40 
(0.35) 
[5.47] 
3.03 
(0.10) 
[3.30] 
6.16 
(0.19) 
[3.08] 
2.97 
(0.16) 
[5.39] 
6.14 
(0.23) 
[3.75] 
2.95 
(0.13) 
[4.41] 
6.61  
(0.30) 
[4.54] 
150 
2.89 
(0.08) 
[2.77] 
6.37 
(0.26) 
[4.08] 
3.01 
(0.16) 
[5.32] 
5.87 
(0.32) 
[5.45] 
2.87 
(0.07) 
[2.44] 
5.68 
(0.17) 
[2.99] 
2.84 
(0.15) 
[5.28] 
5.68 
(0.19) 
[3.34] 
2.85 
(0.13) 
[4.56] 
6.06  
(0.23) 
[3.79] 
300 
2.71 
(0.08) 
[2.95] 
5.57 
(0.40) 
[7.18] 
2.79 
(0.16) 
[5.73] 
5.20 
(0.32) 
[6.15] 
2.68 
(0.06) 
[2.24] 
5.01 
(0.15) 
[2.99] 
2.67 
(0.13) 
[4.87] 
5.10 
(0.24) 
[4.70] 
2.73 
(0.13) 
[4.76] 
5.31  
(0.24) 
[4.52] 
1000 
2.52 
(0.09) 
[3.57] 
4.76 
(0.55) 
[11.55] 
2.56 
(0.16) 
[6.25] 
4.52 
(0.35) 
[7.74] 
2.48 
(0.09) 
[3.63] 
4.33 
(0.17) 
[3.93] 
2.49 
(0.11) 
[4.42] 
4.50 
(0.35) 
[7.78] 
2.59 
(0.15) 
[5.79] 
4.54  
(0.32) 
[7.05] 
 
the Brookfield and Contraves instruments: 1) for blood at native hematocrit, the mean 
difference was -1.4±1.5%; 2) for the low hematocrit suspensions (average hematocrit = 
27.5%), the mean difference seemed to be -0.31±2.8%; 3) for the high hematocrit 
suspensions (average hematocrit = 56.3%), the mean difference was 1.0±4.9%. We were 
unable to reveal any significant associations between the differences in viscosity and 
shear rate at native, low or high hematocrit levels. The average whole blood viscosity 
values obtained by the three viscometer systems could easily be represented by a single 
curve (Figure 5.3.1).   
 
Table 5.3.1: Rheolog™ reproducibility measurements. Data for each donor are for 
10 replicate tests at low and at high hematocrit levels. In each cell, the top value 
represents the mean, the value in “(  )” is the standard deviation, and the number in 
[ ] is the coefficient of variation (i.e., mean/SD times 100). 
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Whole blood viscosity (mPa.s)  Shear Rate (s-1) Device 
Native Hct Low Hct High Hct 
Rheolog A 18.77 (3.82) 7.25 (0.92) 39.67 (4.60) 
Rheolog B 18.41 (4.07) 7.06 (1.30) 39.70 (3.87) 
Rheolog Average 18.59 (3.94) 7.15 (1.11) 39.68 (4.23) 
1.29 
Contraves 18.29 (3.96) 7.24 (1.20) 39.18 (6.18) 
Rheolog A 12.04 (2.06) 5.33 (0.56) 23.43 (2.34) 
Rheolog B 11.88 (2.21) 5.27 (0.72) 23.58 (2.11) 
Rheolog Average 11.96 (2.13) 5.30 (0.64) 23.50 (2.22) 
3.23 
Contraves 12.27 (2.37) 5.32 (0.72) 24.13 (3.01) 
Rheolog A 8.61 (1.26) 4.29 (0.38) 15.48 (1.42) 
Rheolog B 8.54 (1.32) 4.29 (0.44) 15.68 (1.31) 
Rheolog Average 8.57 (1.29) 4.29 (0.41) 15.58 (1.36) 
8.11 
Contraves 8.81 (1.52) 4.20 (0.48) 16.46 (1.84) 
Rheolog A 7.24 (0.97) 3.85 (0.32) 12.41 (1.13) 
Rheolog B 7.21 (0.99) 3.88 (0.34) 12.61 (1.02) 
Rheolog Average 7.22 (0.98) 3.86 (0.33) 12.51 (1.07) 
14.98 
Contraves 7.41 (1.19) 3.76 (0.38) 12.78 (1.30) 
Rheolog A 6.31 (0.80) 3.55 (0.28) 10.36 (0.98) 
Rheolog B 6.30 (0.78) 3.60 (0.27) 10.56 (0.83) 
Rheolog Average 6.30 (0.79) 3.57 (0.27) 10.46 (0.90) 
27.7 
Contraves 6.49 (0.93) 3.45 (0.32) 10.24 (1.00) 
Rheolog A 5.66 (0.69) 3.33 (0.25) 8.98 (0.89) 
Rheolog B 5.65 (0.64) 3.39 (0.23) 9.17 (0.71) 
Rheolog Average 5.65 (0.66) 3.36 (0.24) 9.07 (0.80) 
51.2 
Contraves 5.68 (0.75) 3.38 (0.29) 8.46 (0.76) 
Rheolog A 5.14 (0.58) 3.23 (0.24) 8.05 (0.79) 
Rheolog B 5.13 (0.55) 3.29 (0.22) 8.17 (0.69) 
Rheolog Average 5.13 (0.56) 3.26 (0.23) 8.11 (0.74) 
75 
Brookfield 5.11 (0.51) 3.32 (0.37) 7.31 (0.66) 
Rheolog A 4.47 (0.45) 3.08 (0.23) 6.84 (0.69) 
Rheolog B 4.45 (0.46) 3.16 (0.20) 6.88 (0.68) 
Rheolog Average 4.46 (0.45) 3.12 (0.21) 6.86 (0.68) 
150 
Brookfield 4.47 (0.43) 3.19 (0.27) 6.45 (0.56) 
Rheolog A 4.02 (0.39) 2.86 (0.19) 6.05 (0.65) 
Rheolog B 4.00 (0.43) 2.92 (0.16) 6.04 (0.69) 
Rheolog Average 4.01 (0.41) 2.89 (0.17) 6.04 (0.67) 
300 
Brookfield 4.07 (0.40) 3.04 (0.21) 5.91 (0.51) 
Rheolog A 3.64 (0.36) 2.65 (0.18) 5.39 (0.63) 
Rheolog B 3.62 (0.41) 2.70 (0.14) 5.34 (0.70) 
Rheolog Average 3.63 (0.38) 2.67 (0.16) 5.36 (0.66) 
750 
Brookfield 3.72 (0.40) 2.78 (0.21) 5.42 (0.47) 
Rheolog A 3.46 (0.35) 2.55 (0.19) 5.07 (0.62) 
Rheolog B 3.43 (0.41) 2.59 (0.13) 5.00 (0.71) 
Rheolog Average 3.44 (0.38) 2.57 (0.16) 5.03 (0.66) 
1500 
Brookfield 3.50 (0.35) 2.61 (0.15) 5.13 (0.44) 
Table 5.3.2: Comparison of blood viscosity data obtained by the Rheolog™, 
Contraves and Brookfield systems. Data are mean and SD for 44 donors 
tested at native (mean = 41.2%) and 8 donors at low and high hematocrits. 
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Figure 5.3.3: Effects of storage time and temperature on blood viscosity measured with 
the Rheolog™. Data are mean +SD for 8 donors at native hematocrit; for clarity, only 
results at 3.23s-1 and 750s-1 are shown. The control values in the left-most columns were 
obtained 10 minutes following venipuncture. 
 
5.3.3 Storage 
 The effects of storage time and temperature on whole blood viscosity profiles are 
presented in Figure 5.3.3; for clarity only results obtained at a representative low 
(3.23s-1) and high (750s-1) shear rates are shown. Note that in this figure, the vertical 
“error” bars were calculated as the standard deviation for the measured eight donors, 
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but, as in Figure 5.3.2, primarily reflect differences in the hematocrit of native blood 
among the subjects rather than measurement variability (Table 5.3.1). 
 In general, data in Figure 5.3.3 seem remarkable for the absence of major 
changes of blood viscosity from the control (i.e., 10 minutes post venipuncture) values. 
In fact, paired t-test analyses indicated that only the 3 hour 37°C results at shear rates of 
1.29 and 3.23s-1 had p values less than 0.05. However, some trends were evident: 1) 
changes from control tended to be larger at lower shear rates (e.g., for room temperature 
storage, a 7% average decrease at 3.23s-1 versus only 3% average decrease at 750s-1); 2) 
with the exception of the day three results, changes due to storage at either room 
temperature or 4°C were essentially independent of storage time; 3) the effect of storage 
at 37°C was the greatest at 3 hours (i.e., -17% at 3.23s-1 and -7% at 750s-1) with smaller 
changes noted at 6 hours (i.e., -7% at 3.23s-1 and -3% at 750s-1). 
 
 
5.4 Discussion 
 
The complex measurement of whole blood viscosity profiles summarizes the 
effect of numerous rheological parameters affecting blood flow, such as plasma 
viscosity, red blood cell deformability, erythrocyte aggregation and aggregability. 
Besides the well-known conventional risk factors, hyperviscosity has been proved to 
play a major role in the pathophysiology of ischemic heart disease, stroke and various 
hematological disorders as well. However, the measurement of clinically relevant whole 
blood viscosity profiles with either commercial or prototype rheometers can be 
associated with several artifacts that are often not recognized, especially at lower rates 
of shear. The main sources of error are: 1) Formation of a rigid, denatured protein film 
at the blood-air or plasma-air interface. Such a film can transfer torque or provide 
addition drag on a torque sensing section (e.g., bob of a Couette viscometer, cone of a 
cone-and-plate viscometer), with the effects particularly important at low torque or 
shear rate levels. This film artifact has previously led to erroneous reports of 
non-Newtonian behavior for normal human plasma [27,128]. However, for viscometers 
in which the torque-sensing element remains essentially stationary, the use of a “guard 
ring” can eliminate this problem [128], whereas a guard ring is not usable in 
cone-and-plate systems where the torque-sensing element rotates (e.g., Brookfield 
  62
viscometer). Note that this film can also affect tube viscometers in which pressure 
differences are measured through an air-blood interface. 2) Phase separation leading to 
lower RBC concentration at the torque-sensing element. This phenomenon has been 
described in detail by Cokelet [28] for a Couette viscometer operating at shear rates less 
than about 10s-1. Under these conditions, the observed torque at steady shear exhibits a 
decay with time due to the formation of a cell-poor, lower-viscosity layer at the wall of 
the cup and bob. Use of a torque extrapolation to zero time technique, rather than the 
lower, incorrect final steady state torque, has been shown to yield the proper torque 
value [28,128]. 3) Sedimentation of RBCs in capillary or rotational viscometer systems 
at low flow rates. This phenomenon is most evident in blood samples or RBC 
suspensions having a high degree of erythrocyte aggregation. Sedimentation in capillary 
viscometers can arise in the tube itself or the connecting tubing as well resulting in an 
increased pressure drop for a given flow rate [1]. The effects of sedimentation in 
rotational viscometers depend primarily on their design: in Couette or Mooney systems 
elevated hematocrit at the bottom of the cup can increase the measured torque, whereas 
sedimentation away from the cone of a Brookfield-type viscometer will decrease the 
measured torque. The recently used viscometer systems are further complicated with 
several limitations: measurements are time consuming, require a well-trained, full time 
technician, have a potential biohazard risk and are incapable of measuring whole blood 
viscosity over a wide range of clinically relevant shear rates. 
Based upon the findings obtained in the present study, where Rheolog™ results 
were compared to cone-and-plate and Couette viscometers operated to avoid artifacts, 
the Rheolog™ system appears to be completely free from the instrumental problems 
mentioned above. Data presented in Table 5.3.1 indicate good reproducibility, with 
those in Table 5.3.2 and Figure 5.3.2 demonstrating close agreement between the 
Rheolog™ and the two other viscometer systems over a wide range of shear rates. In 
particular, good agreement was noted at the lower rates of shear where surface film and 
RBC sedimentation can often cause difficulties [28,128]. Based on these findings it is 
evident, that the reproducibility and accuracy of the new scanning capillary rheometer is 
acceptable for clinical use. We should note though, that our conclusions are constrained 
by the scope of the parameters used in the present study (average hematocrit range: 
28%-56%, shear rate range: 1-1500s-1, temperature = 37°C) and that extending our 
conclusions beyond this range may not be warranted. In particular, pilot studies 
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indicated that the present software algorithms and capillary tube diameter are not 
appropriate for hematocrits less than about 20% or for cell-free plasma. However, 
discussions with the Rheolog™ manufacturer have indicated that testing low hematocrit 
suspensions and cell-free plasma are possible with modified software algorithms. 
Results presented in Figure 5.2.3 indicate that whole blood anticoagulated with 
EDTA exhibits quite small changes of blood viscosity when stored for up to 8 hours at 
room temperature or for up to 4 days at 4°C. Conversely, storage at 37°C causes marked 
changes within 3 hours, with these alterations partially reversed at 6 hours. This 
phenomenon might be explained by certain changes occurring at 37°C in the red blood 
cell membrane affecting erythrocyte aggregation and aggregability. Literature reports on 
blood viscosity and storage conditions appear to be limited, and often deal with blood 
containing added preservatives intended for transfusion [106], or do not fully define the 
storage conditions [175]. We are thus unable to compare our findings to those reported 
previously. 
The rapidity of whole blood viscosity testing over a wide range of shear rates 
using the Rheolog™ (i.e., less than 5 minutes for testing and data printout) suggests 
possible “real time” applications. For example, monitoring of therapy for rheumatoid 
arthritis often involves performing an erythrocyte sedimentation rate (ESR) test [169], 
with results only available after the usual one-hour sedimentation period. Rapidly 
accessible blood viscosity data at low shear rates could serve as a surrogate for ESR 
tests, and, if appropriate, would provide guidance for medication changes. The results 
obtained for refrigerated storage at 4°C (Figure 5.3.3) may also have clinical 
implications, in that blood could be sampled at various sites and then transferred to a 
central laboratory for testing. Finally, and perhaps of greatest importance, is the 
possibility that easily performed and rapidly available wide-shear blood viscosity data 
may promote epidemiological studies evaluating associations between blood rheology 
and various diseases. Trials to date have started to explore such associations [142,171], 
but have generally been limited to either measurements of plasma viscosity or blood 
viscosity at a single, high shear rate. 
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6. SUMMARY 
 
 
1. Our study investigating the efficacy of routine antiplatelet medication confirmed 
the existence of both aspirin and thienopyridine non-responder individuals in the 
general population. ASA monotherapy proved to be ineffective in more than one 
third of our patients; however, we could note a direct correlation between the 
prescribed daily drug dose and the ratio of appropriate treatment. Ticlopidine and 
clopidogrel resistance was less frequent, even though previously documented 
ASA non-response was the principal indication for the thienopyridine derivates. 
Our study also demonstrated a positive association between the regularity of 
patient follow-up and the efficacy of routine antiplatelet drugs. These findings 
emphasize the importance of tight medical visits and the significance of 
aggregometry controlled, individually adjusted antiplatelet therapy. 
 
2. Our follow-up study revealed that the inhibition of platelet function achieved by a 
fixed daily dose of ASA progressively decreased in a significant number of 
subjects over the 24-month trial period. The observed decline was in accordance 
with the administered aspirin dose, remarkably higher number of individuals 
converted to non-responder in the patient group on a low daily dose of the drug. In 
contrast, the antiplatelet efficacy of thienopyridine derivates remained constant in 
most cases for the entire follow-up period. Our results highlight the inevitable 
value of platelet function tests throughout the secondary prevention of ischemic 
vascular diseases. 
 
3. Our preliminary data documented a highly significant association between the 
individual responsiveness to the prescribed platelet inhibitory medication 
evaluated ex vivo and the occurrence of undesirable ischemic episodes. By 
improving the efficacy of the applied antiplatelet therapy throughout the 
secondary prevention, the incidence of recurrent clinical episodes might be 
reduced by 40%. Further, prospective studies are mandatory to confirm these 
initial findings in a large patient population. 
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4. All the examined PARP inhibitor compounds reduced ADP-induced platelet 
aggregation in a dose dependent manner. However, on a molar basis the novel 
HO-3089 molecule was proved to have superior antiplatelet efficacy over the 
commercially available agents. The effect of the experimental PARP inhibitors 
was specific on ADP receptors as they were unable to antagonize collagen- or 
epinephrine stimulated thrombocyte responses. In addition, all the examined 
agents were capable of hindering platelet aggregation even if those were 
sensitized to ADP by the pre-administration of heparin. Our findings strongly 
suggest that beyond their myocardial protective effect, the administration of 
PARP inhibitors might be of great value in the treatment of ischemia-reperfusion 
injuries. 
 
5. Replicate measurements with the newly developed scanning capillary rheometer 
indicated an outstanding reproducibility independent of hematocrit and shear rate. 
Results obtained using the Rheolog™ compared favorably with those recorded 
with cone-and-plate and Couette viscometer systems. Storing the anticoagulated 
sample at room temperature for up to 8 hours or at 4°C up to 4 days had merely 
minimal effect on blood viscosity; whereas notable changes were observed when 
stored for 3 hours at 37°C. Our results further indicate that the Rheolog™ 
provides rapid, accurate and reproducible blood viscosity data over a wide range 
of clinically important shear rate profile suggesting its inevitable value for basic 
research and clinical studies as well. 
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